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 Abstract Clinical Cancer Research  
 
Purpose: In chronic myelogenous leukemia (CML), leukemic stem cells (LSC) represent a critical 
target of therapy. However, little is known about markers and targets expressed by LSCs. The 
aim of this project was to identify novel relevant markers of CML LSCs.  
Experimental Design: CML LSCs were examined by flow cytometry, qPCR, and various 
bioassays. In addition, we examined the multipotent CD25+ CML cell line KU812.  
Results: In contrast to normal hematopoietic stem cells, CD34+/CD38− CML LSCs expressed the 
IL-2 receptor alpha chain, IL-2RA (CD25). STAT5 was found to induce expression of CD25 in 
Lin−/Sca-1+/Kit+ stem cells in C57Bl/6 mice. Correspondingly, shRNA-induced STAT5 depletion 
resulted in decreased CD25 expression in KU812 cells. Moreover, the BCR/ABL1 inhibitors 
nilotinib and ponatinib were found to decrease STAT5 activity and CD25 expression in KU812 
cells and primary CML LSCs. A CD25-targeting shRNA was found to augment proliferation of 
KU812 cells in vitro and their engraftment in vivo in NOD/SCID-IL-2Rγ−/−mice. In drug-
screening experiments, the PI3K/mTOR blocker BEZ235 promoted the expression of STAT5 and 
CD25 in CML cells. Finally, we found that BEZ235 produces synergistic antineoplastic effects 
on CML cells when applied in combination with nilotinib or ponatinib.  
Conclusions: CD25 is a novel STAT5-dependent marker of CML LSCs and may be useful for 
LSC detection and LSC isolation in clinical practice and basic science. Moreover, CD25 serves 
as a growth regulator of CML LSCs, which may have biologic and clinical implications and may 
pave the way for the development of new more effective LSC-eradicating treatment strategies in 
CML.  
  
Introduction  
 
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell (SC) disorder defined by the 
reciprocal translocation t(9;22) and the related oncoprotein, BCR/ABL1 (1–3). It is generally 
appreciated that BCR/ABL1 is a major driver responsible for initiation and evolution of CML (2–
4). Correspondingly, the BCR/ABL1-targeting tyrosine kinase inhibitor (TKI) imatinib induces 
major cytogenetic and molecular responses in a majority of patients with chronic phase (CP) 
CML (4, 5). However, although long-term disease control can be achieved in many patients, 
imatinib is usually unable to eliminate CML. This phenomenon is best explained by intrinsic and 
acquired drug resistance in leukemic stem cells, LSC (6–12). The intrinsic form of resistance is 
common to all LSC fractions and is considered to be independent of BCR/ABL1. By contrast, the 
acquired form of TKI resistance is caused by newly acquired, subclone-specific defects, 
including BCR/ABL1 mutations (7–13).  
The 'LSC hypothesis' is based on the observation that only a subset by leukemic progenitors 
exhibits long-term disease-propagating capacity (14–16). This concept has major implications for 
the development of curative treatment approaches (7–19). LSC research is currently focusing on 
LSC-specific targets and drugs capable of attacking LSCs (17–19). In CML and other leukemias, 
the development of such LSC-targeting concepts is a major challenge (17–19). Notably, many 
different factors, including multiple signaling cascades and the so-called SC niche, regulate the 
development and expansion of LSCs in CML (9–11, 17–19).  
One important regulator of survival and growth of CML LSCs appears to be the transcription 
factor STAT5 (20–23). A number of previous and more recent studies have shown that 
BCR/ABL1 triggers STAT5 activity in CML cells (20–23). In addition, however, STAT5 
expression and activation may be regulated independently of BCR/ABL1 in CML cells (11, 24). 
Especially in LSCs, STAT5 expression may be induced by BCR/ABL1-independent 
mechanisms. Recent data suggest that STAT5 triggers production of reactive oxygen species and 
clonal instability and thereby promotes the occurrence of BCR/ABL1 mutations (24).  
CML LSCs are considered to represent a small subset of CD34+/CD38− cells in the leukemic 
clone (7–10, 25–27). However, since normal bone marrow stem cells (BM SCs) also display this 
phenotype, additional markers need to be applied to differentiate normal BM SCs from CML 
LSCs. Recent studies have shown that CML LSCs specifically express IL-1RAP and dipeptidyl-
peptidase IV, DPPIV = CD26 (28–30). As assessed by gene array analyses, CML LSCs may 
express additional markers (30–32). One of these aberrant markers appears to be the low-affinity 
receptor for IL-2, CD25 (30–32). However, little is known about the functional role of CD25 in 
human CML LSCs and the mechanisms contributing to abnormal CD25 expression.  
In this study, we show that expression of CD25 on CML LSCs is triggered by STAT5 and that 
CD25 acts as a negative regulator of LSC growth in CML. In addition, we show that BCR/ABL1 
TKIs downregulate STAT5- and CD25 expression in LSCs, whereas the PI3K/mTOR blocker 
BEZ235 promotes CD25 expression.  
 
Translational Relevance  
Although chronic myelogenous leukemia (CML) is a stem cell disease, little is known about the 
expression and function of specific markers and targets in CML LSCs. We here describe that 
CD25 serves as a novel robust marker of CML LSCs that can be used for detection, enumeration, 
and isolation of LSCs in these patients. Moreover, CD25 was found to serve as a drug-inducible 
suppressor of LSC expansion, which may be relevant clinically and may pave the way for the 
development of new treatment strategies. Based on our work, a straightforward approach might 
be to combine BCR/ABL1 tyrosine kinase inhibitor that downregulates CD25 expression with 
targeted drugs promoting CD25 expression, such as the PI3K/mTOR blocker BEZ235. Indeed, 
these drug combinations produced highly synergistic antiproliferative effects on KU812 cells in 
the present study.  
 
 
 
 
  
Materials and Methods  
 
Reagents  
A detailed description of reagents used in this study is provided in the Supplement. Monoclonal 
antibodies (mAb) used in this study are described in Supplementary Table S1.  
 
Cell lines  
The multipotent human BCR/ABL1+ cell line KU812 was kindly provided by Dr. K. Kishi 
(Niigata University, Niigata, Japan) in 1989; K562 cells and murine Ba/F3 cells expressing 
various BCR/ABL1 mutants (M244V, G250E, Q252H, Y253H, E255K, E255V, T315I, F317L, 
F317V, F359V, and H396P) or wild- type BCR/ABL1 were kindly provided by Dr. M. Deininger 
(Hunts- man Cancer Institute, University of Utah, Salt Lake City, UT) in 2013; and imatinib-
resistant K562 cells (K562-R) were kindly provided by Dr. J. D. Griffin (Dana-Farber Cancer 
Center, Harvard Medical School, Boston, MA) in 1999. KCL-22 cells were purchased from the 
German Collection of Microorganism and Cell Culture (DSMZ) in 2010. The identity of KU812, 
K562, and K562- R cells was confirmed by DSMZ using nonaplex-PCR in 2010. All experiments 
were performed from these stocks, and cells were thawed from these stocks (or secondary stocks) 
every 1 to 3 months. Cell lines were maintained in RPMI 1640 medium, 10% fetal calf serum 
(FCS), and antibiotics at 37°C. K562-R cells were cultured in the presence of 1 µmol/L imatinib. 
Mouse M2-10B4 feeder cells were purchased from the American Type Culture Collection. 
Ecotropic retroviral packaging cell lines GP+/E86 encoding for STAT5A-IRES-GFP, STAT5B-
IRES-GFP (33), or the empty vector, and GP+/E86 cells encoding for p210BCR/ABL1-IRES- dsRED 
(23) were maintained in complete medium supplemented with 10% FCS as described (23, 33).  
 
Patients and cell sampling  
Sixty-three patients with BCR/ABL1+ CML (32 females, 31 males) were examined for 
expression of CD25 on CD34+/CD38− CML LSCs and CD34+/CD38+ CML progenitor cells. The 
median age was 54 years (range, 18–86 years). Most patients were examined at diagnosis (before 
treated with BCR/ABL1 TKI). The patients' characteristics are shown in Supplementary Table 
S2. Peripheral blood (PB) and/or BM cells (iliac crest or sternum) were collected at diagnosis and 
in the follow-up. Control samples included normal/reactive BM and other myeloid neoplasms 
(Supplementary Table S3). All donors gave written informed consent, and all studies were 
approved by the ethics committees of the Medical University of Vienna and the University of 
Veterinary Medicine Vienna.  
 
Flow cytometry experiments  
Phenotyping of CD34+/CD45+/CD38− (L)SCs and CD34+/CD45+/CD38+ progenitor cells was 
performed on BM or PB cells (unseparated or Ficoll-isolated) by multicolor flow cytometry as 
described (34, 35) using fluorochrome-conjugated mAb shown in Supplementary Table S1. Flow 
cytometry was performed on a FACSCalibur (Becton Dickinson). A detailed description of the 
staining techniques is provided in the Supplement.  
 
Retroviral infection of murine BM cells  
Retroviral packaging GP+/E86 cells encoding for STAT5A-IRES- GFP, STAT5B-IRES-GFP 
(33), or empty vector were mixed 1:1 with GP+/E86 cells encoding p210BCR/ABL1-IRES-dsRED 
(23) and seeded on gelatine (0.2%) precoated dishes. Single-cell suspensions from total wild-type 
BM cells of C57Bl/6N mice were prepared, and 3x106 cells/mL were cocultured with GP+/E86 
cells in DMEM supplemented with murine IL-3 (25 ng/mL), IL-6 (50 ng/mL), stem cell factor, 
SCF (50 ng/mL), and polybrene (7 µg/mL) for 72 hours. Thereafter, BM cells were stained with 
mAb PC61 directed against CD25 and analyzed by flow cytometry using a BD FACS-Canto II 
FACS device and BD FACS Diva software (Becton Dickinson). Six-to-eight–week-old male 
C57Bl/6N mice (20 g) were purchased from the Jackson Laboratory.  
 
Gene array analyses  
KU812 cells transduced with a random (RDM) shRNA or a CD25 shRNA were subjected to 
RNA isolation and gene array analysis using Affymetrix technology. Details are provided in the 
Supplement. A complete set of mRNA data is available at Gene Expression Omnibus, accession 
number: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token1⁄4orotekeollgdduf&acc1⁄4GSE60315.  
 
Quantitative PCR and cytogenetics  
RNA was isolated from CML cell lines, primary CML (stem) cells, and pooled colony-derived 
cells. CD25-, CD122-, CD132-, and BCR/ABL1 mRNA expression levels were measured by 
qPCR as reported (29, 35). Conventional cytogenetics and FISH were performed according to 
published protocols (36). A detailed description of the methods applied is provided in the 
Supplement.  
 
Transfection studies  
Knockdown studies with shRNAs were performed following published techniques (37, 38). In 
CD25 knockdown studies, 3 shRNAs against human CD25 (clone #1: 5’-AAATCTGTTGTTGT- 
GACGAGG-3’ ; clone #2: 5’ -TTTCTGTTCTTCAGGTTGAGG-3’ ; clone #5: 5’-
TACTCTGTTGTAAATATGGAC-3’; Open Biosystems) expressed in pLKO.1 lentiviral vector 
containing the puromycine-resistance gene were applied. In select experiments (CD34+ cells), the 
puromycine-resistance gene was replaced by mCherry. For knockdown of STAT5, an shRNA 
targeting STAT5A and STAT5B (5’ -GCAGCAGACCATCATCCTG-3’ ; ref. 37) expressed in 
pLKO.1 containing the puromycine-resistance gene was used. The shRNA-mediated knockdown 
of CD25 was induced in KU812 cells and primary CD34+ CML cells, and knockdown of 
STAT5A/STAT5B in KU812 cells. Transfected KU812 cells were selected by exposure to 
puromycin (2 µg/mL), and transduced primary CD34+ CML cells by sorting for mCherry. 
Knockdown was confirmed by flow cytometry (CD25) or Western blotting (STAT5) according to 
published techniques (39). To evaluate the functional consequence of the CD25 knockdown, 
CD25 shRNA (clones #1, #2, and #5)-transduced KU812 cells and KU812 transduced with 
random (RDM) shRNA were mixed at 1:1 and cultured. Cell mixtures were periodically 
examined for CD25 expression by flow cytometry using phycoerythrin (PE)-conjugated mAb 
2A3 against CD25. To study proliferation of KU812 cells and primary CD34+ CML cells 
transduced with CD25 shRNA (clone #2) or RDM shRNA, 3H-thymidine uptake experiments 
were performed. In a separate set of experiments, CD25 was lentivirally expressed in K562, 
K562-R, and KCL-22 cells. A precision LentiORF IL-2RA (CD25) gene construct (GFP tag) and 
a control construct was obtained from GE Dharmacon. Virus production and transduction of cells 
were performed as described above, and GFP+ cells were selected by cell sorting. Purified cells 
were applied in mixing experiments (1:1 of empty vector control-transduced cells and CD25-
transduced cells) as described above and analyzed 3 times/week using APC-conjugated CD25 
mAb BC96.  
Xenotransplantation assay  
To investigate the functional role of CD25 in CML cells in vivo, KU812 cells transduced with 
shRNA against CD25 (clone #2) or with RDM shRNA were injected intravenously into 
nonirradiated nonobese diabetic NOD/SCID-IL-2Rγ−/− (NSG) mice (5 per group). Ten-to-twelve-
week-old, female NSG mice (20–30 g) were purchased from the Jackson Laboratory. Cells were 
resuspended in 0.15 mL RPMI with 10% FCS and antibiotics and injected into the tail vein of 
NSG mice (1x106 cells/mouse). After 6 weeks, blood was drawn to analyze engraftment. Then, 
mice were sacrificed and BM cells (tibia, femur, pelvis) and spleens were isolated and prepared 
for immunohistochemistry and flow cytometry. The size and weight of spleens were measured in 
each animal. Then, splenic samples were prepared as follows: each spleen was cut into small 
pieces with a scalpel and mashed through a small-sized filter to obtain single-cell suspensions. 
Long bones were flushed to recover BM cells for flow cytometry in order to document 
engraftment. Multicolor flow cytometry was performed using mAb 515 against CD44 for 
detection of KU812 cells. TO-PRO-3 (Invitrogen) was used to exclude nonviable cells.  
Long-term culture-initiating cell assay 
To investigate the long-term growth of sorted CD34+/CD38−/CD25+ LSCs and 
CD34+/CD38−/CD25− (presumably normal) SCs obtained from 2 patients with CP CML, a long-
term culture-initiating cell (LTC-IC) assay was performed as described (29). A detailed 
description of the method applied is provided in the Supplement.  
 
Statistical evaluations   
To determine the level of significance in differences in CD25 expression and pSTAT5 levels in 
LSCs in various donor-groups or before and after drug exposure, the Student t test was applied. 
Results were considered to be significantly different, when P < 0.05. Drug combination 
experiments were performed following published guidelines (40). Drug interactions were 
determined by calculating combination index (CI) values using Calcusyn software (Calcusyn; 
Biosoft) as described previously (40, 41). A CI of less than 1 indicates synergy, a CI of 1 an 
additive effect, and a CI of more than 1 an antagonistic effect.  
 
 
 
Results  
 
Human CML LSCs express IL-2RA (CD25)  
As assessed by flow cytometry, CD34+/CD38− LSCs expressed CD25 in 50 of 54 patients with 
CML (92.6%; Fig. 1A and B). CD25 was detected on LSCs in patients with CP (40/43), 
accelerated phase (AP, 2/3), and blast phase (BP, 8/8). As expected, highly enriched CML LSCs 
expressed CD25 mRNA in all samples tested (Fig. 1C). CD34+/CD38+ CML progenitor cells 
expressed only trace amounts or no detectable CD25 (Fig. 1C and D). During treatment with 
imatinib (14 patients) or other TKIs (3 patients), the numbers of CD25+ LSCs decreased in the 
BM compared to pretreatment values (Fig. 1E). CML LSCs did not express IL-2RB (CD122) or 
IL-2RG (CD132) at the mRNA level (Fig. 1C) or protein level (Table 1). In the normal/reactive 
BM, CD34+/CD38− SCs did not express CD25 (Fig. 1B). Moreover, CD25 was not detectable on 
CD34+/CD38− SCs in various control groups, including 13 of 14 patients with idiopathic 
cytopenia of unknown significance (ICUS), other classical myeloproliferative neoplasms (MPN), 
or mastocytosis (Fig. 1B).  
Aberrant expression of CD25 on CML cells is restricted to LSCs  
As assessed by multicolor flow cytometry, CD25+ CML LSCs coexpressed two other well-
established LSC antigens, IL-1RAP and DPPIV (CD26). In addition, CD25+ CML LSCs 
coexpressed Siglec-3/CD33, CD44, CD52, and KIT/CD117 (Table 1; Supplementary Fig. S1). 
Among more mature myeloid cells in the CML clone, only basophils were found to express 
CD25, with slightly higher expression levels observed in CML basophils compared with normal 
basophils (Table 2). In all other myeloid lineages examined, including monocytes and mast cells, 
CD25 was not detectable in our CML patients. These data suggest that aberrant expression of 
CD25 in the CML clone is restricted to LSCs. In a subset of patients, we separated the CD25+ 
and the CD25− SC fractions from the same samples to near homogeneity (>95% purity) by cell 
sorting. In these experiments, all CD25+ LSCs (100%) contained BCR/ABL1 by FISH, whereas 
only 45% of the CD25 SCs expressed BCR/ABL1 (Supplementary Fig. S2; Supplementary Table 
S4). The long-term proliferative (LTC-IC) capabilities of CD25+ CML LSCs and normal CD25− 
SCs obtained from the same patients are shown in Supplementary Fig. S3.  
 
STAT5 activity contributes to the expression of CD25 in LSCs  
Because CD25 is a STAT5 target gene, we applied shRNA against STAT5, which led to a 
substantial knockdown of STAT5 expression in KU812 cells (Supplementary Fig. S4). The 
STAT5 knockdown resulted in a decreased expression of CD25 at the mRNA and protein level 
(Fig. 2A). A STAT5-targeting drug, pimozide, was also found to downregulate CD25 expression 
in KU812 cells (Fig. 2B). A similar effect was seen with the MEK inhibitors PD0325901 and 
RDEA119 (Fig. 2C), whereas the PI3K/mTOR blocker BEZ235 did not inhibit CD25 expression. 
Rather, BEZ235, the mTOR-targeting drug RAD001, and the PI3K inhibitor LY294002, were 
found to upregulate expression of CD25 in KU812 cells (Fig. 2D) as well as in the other CML 
cell lines examined (Supplementary Fig. S5A). Similar results were obtained with primary CML 
LSCs. Again, the STAT5 blocker pimozide decreased CD25 expression (Fig. 3A), and BEZ235 
and RAD001 were found to augment CD25 expression on CD34+/CD38− CML LSCs (Fig. 3B). 
Finally, BEZ235 was found to upregulate CD25 expression on Ba/F3 cells containing various 
BCR/ABL1 mutants, including E255K, F317L, and T315I (Supplementary Fig. S5B). As 
expected, BEZ235 was also found to inhibit proliferation in these cells (Supplementary Fig. 
S5C). Together, these data suggest that expression of CD25 on CML LSCs is regulated by a 
signaling cascade involving STAT5, PI3K, and mTOR.  
Effects of BCR/ABL1-targeting TKIs on expression of pSTAT5 and CD25 in CML cells  
All three BCR/ABL1 TKIs tested (imatinib, nilotinib, and ponatinib) were found to inhibit the 
expression of pSTAT5 and of CD25 in KU812 cells (Fig. 3C). Nilotinib and ponatinib were also 
found to block CD25 expression in primary CML LSCs (Fig. 3D). However, the weaker 
BCR/ABL1 blocker imatinib showed no significant effect on expression of CD25 on primary 
CML LSCs (Fig. 3D). All three TKIs were found to downregulate expression of pSTAT5 in 
primary CML LSCs (Fig. 3E). Finally, we found that imatinib, nilotinib, and ponatinib 
downregulate the expression of CD25 in Ba/F3 cells expressing various mutant forms of 
BCR/ABL1, including E255K, G250E, F317V, and F317L (Supplementary Fig. S6).  
 
Retroviral infection of murine SCs with STAT5 is followed by upregulation of CD25  
Infection of BM stem cells of C57Bl/6 mice with a retroviral vector encoding either STAT5A or 
STAT5B, or coinfection of BCR/ABL1-p210 and STAT5, resulted in an enhanced expression of 
CD25 on Lin−/Sca-1+/Kit+ (LSK) cells (Fig. 4). There was no difference in expression of CD25 
on LSK cells when comparing cells infected with STAT5 alone with cells infected with both, 
STAT5 and BCR/ABL1 (Fig. 4). Interestingly, infection of BM cells with BCR/ABL1 alone was 
not followed by a major increase in expression of CD25 on LSK cells (Fig. 4). In line with this 
observation, infection with BCR/ABL1 alone also failed to substantially increase the expression 
of STAT5 in LSK cells (not shown). These data suggest that expression of CD25 in LSK cells is 
triggered by STAT5 activity in the absence and presence of BCR/ ABL1 in C57Bl/6 mice.  
Identification of CD25 as a regulator of growth of CML cells  
We next examined the potential biologic function of CD25 on CML LSCs. In initial experiments, 
we were unable to demonstrate any effects of IL-2 on growth of KU812 cells, K562 cells, or 
primary CML cells (Supplementary Fig. S7). In addition, preincubation with IL-2 did not alter 
responses of primary CML cells to the PI3K/mTOR inhibitor BEZ235 (Supplementary Fig. S7). 
Finally, we applied a random (RDM) shRNA and 3 different CD25-specific shRNAs (clone #1, 
#2, and #5) on KU812 cells. In these experiments, the knockdown of CD25 resulted in an 
increased proliferative capacity compared with cells transduced with an RDM shRNA (Fig. 5A). 
We also confirmed the growth advantage of CD25-negative KU812 cells in vivo in an NSG 
xenotransplantation model. NSG mice injected with CD25 shRNA–transfected (clone #2) KU812 
cells showed significantly higher engraftment levels in the BM, PB, and spleen when compared 
with mice injected with control cells (Fig. 5B). In a next step, we transduced CD34+ SC from 2 
patients with CML CP (23%–30% of the CD34+ cells expressed CD25; and >80% of the 
CD34+/CD38− cells expressed CD25) with a specific CD25 shRNA (clone #2) or an RDM 
control shRNA. The knockdown of CD25 resulted in an enhanced proliferation of these CD34+ 
CML cells (Fig. 5C). Finally, we expressed CD25 in the CD25-negative (or weakly CD25-
positive) CML cell lines K562, K562-R, and KCL-22 by lentivirus-mediated transduction. In all 
three cell lines tested, transduction with CD25 resulted in decreased proliferation (Supplementary 
Fig. S8). Together, these data strongly suggest that CD25 acts as a "leukemia-suppressing" 
molecule in CML (stem) cells.  
Identification of CD25-regulated target genes in KU812 cells  
In an attempt to define the mechanism of CD25-induced growth inhibition in CML cells, we 
performed gene array analyses using KU812 cells transfected with RDM shRNA or CD25 
shRNA (clone #2). In these analyses, a number of up- and down- regulated mRNA species were 
identified in CD25-depleted cells (Supplementary Table S5). Among the top upregulated gene 
products, a number of mediators of cell growth, proliferation, or survival were identified, 
including several members of the DAZ- family, RAB27B, IGFBP7, SSX2, RASGEF1A, or IGF-
1 (Supplementary Table S5A). Downregulated genes included several "tumor-suppressor" genes, 
genes involved in lymphocyte activation, inflammatory response, and cell signalling 
(Supplementary Table S5B). Together, these data suggest that multiple target genes may 
contribute to CD25-induced growth inhibition in CML cells. In a next step, we performed 
pathway analyses in order to detect additional genes or gene patterns relevant to CD25-induced 
growth inhibition. However, no additional genes or pathways potentially involved in CD25-
induced suppression of SC growth could be identified (Supplementary Fig. S9). We also 
compared cell-cycle progression, mitosis, and apoptosis in shRNA-transduced versus RDM 
control shRNA-transduced KU812 cells. In these experiments, we were able to show that the 
shRNA-induced knockdown of CD25 resulted in a slightly increased number of mitotic cells 
compared with RDM-transduced cells (Supplementary Fig. S10). By contrast, we were unable to 
detect any changes in the percentage of apoptotic cells after CD25 shRNA transduction 
(Supplementary Fig. S10). Finally, shRNA-induced knockdown of CD25 did not alter cell-cycle 
progression in KU812 cells (Supplementary Fig. S10).  
Identification of CD25 as a BEZ235-induced growth inhibitor: a rationale for the design of 
drug combinations with synergistic effects  
In a final step, we asked whether CD25 can serve as a secondary "drug effector" blocking the 
growth of CML cells. The shRNA-induced knockdown of CD25 in KU812 cells was not 
followed by any changes in their responses to imatinib, nilotinib, or ponatinib (comparable IC50 
values; Supplementary Fig. S11A). However, the shRNA-induced knockdown of CD25 resulted 
in a decreased response of KU812 cells to BEZ235 (Supplementary Fig. S11A). Since BEZ235 
upregulates CD25 in KU812 cells, these data suggest that CD25 may serve as a secondary target 
mediating BEZ235-induced growth inhibition. Because we also noted that BCR/ABL1 TKIs 
decrease CD25 expression, we asked whether combined application of BEZ235 and BCR/ABL1 
TKIs would result in cooperative growth-inhibitory effects. Indeed, combinations of BEZ235 and 
nilotinib and BEZ235 and ponatinib resulted in strong synergistic growth-inhibitory effects in 
KU812 cells (Supplementary Fig. S11B).  
  
Discussion  
 
Although LSCs are an emerging new target of therapy, little is known about disease-specific 
markers and targets expressed in CML LSCs. We here show that CML LSCs aberrantly express 
CD25 and that STAT5 triggers the expression of CD25 on LSCs. Moreover, we show that 
shRNA-induced CD25-depletion in CML cells is associated with enhanced proliferation in vitro 
and enhanced engraftment of KU812 cells in NSG mice. These data suggest that CD25 is a novel 
biomarker of CML LSCs and that it acts as a 'leukemia-suppressing' molecule, which may have 
clinical and diagnostic implications. 
Recently, gene array studies have shown that CML LSCs express CD25 mRNA in excess over 
normal SCs (30–32). In the current study, we confirmed these results at the mRNA and protein 
level. In particular, CD25 was found to be expressed on CML LSCs in almost all patients tested, 
independent of the phase of disease. The levels of CD25 on LSCs varied from donor to donor, but 
CD25 was detectable in >90% of all patients with CML. By contrast, in most control samples 
tested, normal CD34+/CD38− BM SCs did not express CD25. After successful treatment with 
imatinib, the numbers of CD25+ SCs in the BM decreased substantially in our CML patients. 
However, in a few patients entering a major molecular response (BCR/ABL1 <0.1%), 
CD34+/CD38− SCs still expressed CD25, even when CD26 and IL-1RAP were no longer 
detectable. This phenomenon may have several explanations. First, these cells may represent an 
early (BCR/ABL1-negative) phase of LSC evolution (42, 43). An alternative explanation would 
be that normal SCs in these patients were in an activated state and therefore expressed CD25. 
Recent data suggest that LSCs in patients with acute myeloid leukemia express CD25 (44). In the 
present study, we asked whether CD25 is specifically expressed on CML LSCs among MPNs. 
However, we were neither able to detect CD25 on SCs in patients with JAK2-mutated MPNs nor 
in patients with systemic mastocytosis, which was an unexpected result, because STAT5 
activation occurs downstream of JAK2 V617F and KIT D816V. One explanation may be that 
additional (disease- or cell-specific) factors, apart from STAT5, are required for induction of 
CD25 expression in LSCs. We therefore asked whether aberrant expression of CD25 is detectable 
in various lineages in the CML clone. However, we were unable to detect substantial amounts of 
CD25 in other cell types in our CML patients, including CD34+/CD38+ progenitor cells and more 
mature myeloid cells in the CML clone. These data suggest that aberrant expression of CD25 is 
confined to the LSC fraction in CML.  
A number of previous studies have shown that CD25 is a STAT5 target gene (45, 46). Other 
studies have shown that BCR/ABL1 directly triggers STAT5 activation (20–23). In the present 
study, we were able to show that expression of CD25 on CML LSCs is dependent on STAT5 
activity. First, the shRNA-induced knockdown of STAT5 resulted in a decreased expression of 
CD25. Furthermore, the STAT5-targeting drug pimozide was found to inhibit expression of 
CD25 in KU812 cells and primary CML LSCs. Finally, infection of murine BM SCs with 
STAT5A or STAT5B resulted in an enhanced expression of CD25. An interesting observation 
was that CD25 expression on murine CML LSCs (LSK cells) was induced by STAT5 rather than 
by BCR/ABL1, contrasting recently published results (32). One explanation for these discrepant 
data would be differences in the transfection assay or transfection efficacy. Another explanation 
may be that BCR/ABL1 triggers STAT5 activation rather than STAT5 production in LSK cells.  
Imatinib and other BCR/ABL1 TKIs remain the standard of treatment in patients with Ph+ CML 
(4, 5, 47). However, the potency of nilotinib and ponatinib against BCR/ABL1 clearly exceeds 
the potency of imatinib (48–50). We asked whether exposure to TKIs would result in a decreased 
expression of activated STAT5 and CD25. In KU812 cells, all three TKIs were found to inhibit 
the expression of pSTAT5 and expression of CD25, without major differences in IC50 values. In 
primary patient-derived LSCs, however, ponatinib was the most potent compound, followed by 
nilotinib, whereas imatinib showed only little if any effect. These data may be explained by the 
fact that ponatinib and nilotinib are more potent inhibitors of BCR/ABL1. Alternatively, CD25 
expression in LSCs is dependent not only on BCR/ABL1 and STAT5 but also on other targets 
recognized by ponatinib and nilotinib, but not imatinib.  
Next, we explored the functional role of CD25 in CML LSCs. In a proliferation assay, IL-2 did 
not modulate growth of CML cells even when applied at high concentrations. In line with this 
observation, CML LSCs and KU812 cells stained negative for IL-2RB (CD122) and IL-2RG 
(CD132). Recent data suggest that CD25 expression on LSK cells correlates with their 
proliferative capacity in vivo (32). By contrast, we observed a growth-promoting effect of various 
CD25 shRNAs in KU812 cells. In fact, the shRNA-induced knockdown of CD25 was found to be 
associated with an enhanced proliferation in vitro and with a significantly increased engraftment 
of KU812 cells in NSG mice. These data suggest that CD25 is involved in the regulation of 
growth of KU812 cells. Moreover, we were able to show that lentivirus-mediated expression of 
CD25 in the CD25-negative cell lines K562, K562-R, and KCL-22 leads to reduced proliferation. 
Finally, we were able to show that a knockdown of CD25 in primary CD34+ CML stem- and 
progenitor cells is associated with enhanced growth. All in all, these data suggest that CD25 is a 
negative regulator of growth of CML stem cells.  
We next attempted to explore mechanisms underlying the CD25-mediated growth inhibition. In 
these analyses, slightly different numbers in mitotic KU812 cells were found, whereas we were 
unable to detect any major differences in cell-cycle distribution when comparing CD25 shRNA-
transduced cells with RDM shRNA–transduced cells. Alternatively, CD25 may serve as a 
receptor for an as yet unknown negative regulator of stem cell survival or proliferation. In order 
to address these questions, we performed gene array studies on shRNA-transduced KU812 cells. 
In these studies, we were able to identify a number of regulated genes that might be responsible 
for the different growth kinetics (mitotic rate) in KU812 cells. These genes include several 
members of the DAZ family, RAB27B, IGFBP7, SSX2, RASGEF1A, and IGF-1. We 
hypothesize that these genes act together to promote growth in CD25-depleted CML cells. In 
fact, no other critical genes or pathways that could explain the CD25-mediated growth inhibition 
in KU812 cells were identified in this study.  
Because CD25 expression in CML cells may be associated with reduced growth, we screened for 
drugs that would upregulate CD25 expression in CML cells. Whereas most drugs were found to 
downregulate the expression of STAT5 and CD25 in CML cells, the PI3K/mTOR blocker 
BEZ235, the mTOR-targeting drug RAD001 (everolimus), and the PI3K inhibitor LY924002 
were found to upregulate CD25 expression. We were therefore interested to learn whether drug-
induced upregulation of CD25 contributes to the antineoplastic effects of these two agents. 
Indeed, we found that shRNAs against CD25 reduce the sensitivity of KU812 cells against 
BEZ235, suggesting that CD25 may act as secondary drug effector of BEZ235. Based on these 
observations, we were interested to know whether BEZ235-induced upregulation of CD25 may 
enhance the effects of BCR/ABL1 TKIs that were found to downregulate CD25 expression. To 
address this question, we performed drug combination experiments and found that BCR/ABL1 
TKIs synergize with BEZ235 in producing growth inhibition in CML cells. Although it remains 
unknown whether CD25 is indeed a critical target mediating drug synergy, our data suggest that 
these two types of drugs utilize different mechanisms of action, which may explain synergistic 
effects. A related hypothesis would be that TKI-induced CD25 downregulation in CML LSCs is 
part of an escape mechanism, and that this escape is disrupted by addition of PI3K/mTOR 
blockers.  
Together, our data show that CML LSCs aberrantly express CD25 and that STAT5 triggers 
expression of CD25 in CML LSCs. Moreover, our data show that CD25 expression in LSCs is 
functionally relevant and associated with decreased proliferative capacity. These data may have 
implications for the biology of CML and should facilitate LSC detection and isolation. Moreover, 
CD25 may serve as a potential indirect drug target of drug therapy.  
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Tables 
 
Table 1 
 
Expression of surface antigens on CD34+/CD38− and CD34+/CD38+ cells in patients with CML and in normal/reactive BM 
 
 
          CP CML         AP CML         BP CML        normal/reactive BM 
      --------------------------------------- --------------------------------------- --------------------------------------- ------------------------------------------ 
CD  antigen  CD34+/CD38− CD34+/CD38+  CD34+/CD38− CD34+/CD38+  CD34+/CD38− CD34+/CD38+  CD34+/CD38− CD34+/CD38+ 
 
CD25  IL-2RA    ++     +/−     ++     +      ++     ++      −     +/− 
CD26  DPPIV    ++     +/−     ++     +/−     +     +/−     −     − 
CD33  Siglec-3    ++     ++      ++     ++      +     +      +     ++ 
CD44  Pgp1     ++     ++      ++     ++      ++     ++      ++     ++ 
CD52  Campath-1   +     +/−     n.t.    n.t.     +     +      +     + 
CD122  IL-2RB    −     −      n.t.    n.t.     −     −                           −     −   
CD132  IL-2RG    −     −      n.t.    n.t.     n.t.    n.t.     −     − 
CD117  KIT/SCFR   ++     ++      ++     ++      n.t.    n.t.     ++     ++ 
n.c.   IL-1RAP    +     +      n.t.    n.t.     ++     ++      −     +/− 
 
Abbreviations: IL-1RAP, IL-1 receptor accessory protein; IL-2RB, IL-2 receptor beta; IL-2RG, IL-2 receptor gamma; n.c., not yet clustered; n.t., not 
tested; SCFR, stem cell factor receptor; ++, strongly expressed in a majority of cases; +, clear expression in majority of cases; +/ −, expression in 
minority of cases or weak expression in majority of cases; −, no expression in a vast majority of cases.  
 
 
Table 2 
 
Expression of CD25, CD122 and CD132 on various cell types in CML and comparison to 
cells obtained from healthy donorsa 
------------------------------------------------------------------------------------------------------------ 
Types of cell    Expression of:   CD25     CD122    CD132 
------------------------------------------------------------------------------------------------------------ 
Control 
  CD3+  T cells       +/−      +/−     + 
  CD19+  B cells       +/−      −      +/− 
  CD14+ Monocytes      −       −      +/− 
  CD123+ Basophils      +       −      +/− 
CML 
  CD3+  T cells       +/−      +/−     +/− 
  CD19+  B cells       +/−      −      +/− 
  CD14+ Monocytes      −       −      − 
  CD123+ Basophils      ++      −      +/− 
------------------------------------------------------------------------------------------------------------ 
Abbreviation: CML, chronic myeloid leukemia. 
aExpression of CD25, CD122, and CD132 was examined on PB or BM cell subsets by 
multicolor flow cytometry using monoclonal antibodies shown in Supplementary Table 
S1. Cells were analyzed in freshly obtained PB or BM samples (CML, n = 5; healthy 
controls, n = 5). Expression of CD25, CD122, and CD132 was determined as median 
fluorescence intensity (MFI) and is expressed as staining-index (SI), according to the 
formula: SI = MFI (test mAb)/MFI (isotype-control mAb). Results were scored as 
follows: 
SI 0–1.3, − 
SI 1.3–3, +/− 
SI 3–10, + 
SI >10, ++. 
 
  
 
Figurelegends 
 
Figure 1 
CD34+/CD38− stem cells in CML express CD25 
A, CD25 expression on CD34+/CD38− LSCs in 3 patients with CP CML, 3 in AP, and 3 
in BP. Black histograms represent isotype-matched control antibodies, and red 
histograms represent CD25 expression. Patient numbers (#) refer to Supplementary Table 
S2. B, CD25 expression on CD34+/CD38− LSCs in patients with CML (CP, n = 43; AP, n 
= 3; BP, n = 8), SCs in normal/reactive BM (n = 24), idiopathic cytopenia (ICUS, n = 
14), JAK2 V617F+ MPNs (n = 6), and indolent mastocytosis (ISM, n = 7). Results show 
the percentage of CD25+ SCs. Horizontal bars indicate median values in each group. C, 
qPCR analysis of CD25 (left), CD122 (middle), and CD132 (right) mRNA expression in 
sorted CD34+/CD38− LSCs, CD34+/CD38+ progenitors, CD34+ cells, and total 
mononuclear cells (MNC) obtained from 3 patients with CML. mRNA levels are 
expressed as a percentage of ABL1 and represent the mean ± SD from three experiments. 
D, expression of CD25 on CD34+/CD38− LSCs (left) and CD34+/CD38+ cells (right) in 3 
patients with CML. Black open histograms represent isotype-matched control antibodies, 
red histograms CD25 expression on CD34+/CD38− LSCs (left), and blue histograms 
CD25 expression on CD34+/CD38+ progenitors (right). E, percentage of CD25+ SCs at 
diagnosis, after therapy for at least 9 months in all patients (n = 17, top), and at the time 
of major molecular response (MMR) and complete cytogenetic response (CCyR) (n = 12, 
bottom). Patients were treated with imatinib (400 mg/day, n = 14), dasatinib (100 mg/day, 
n =1), or nilotinib (2x 400 mg/day; n = 2).  
 
Figure 2  
Expression of CD25 on CML cells is dependent on STAT5 activity 
A, KU812 cells transduced with shRNA against STAT5 or a random control (RDM) 
shRNA were analyzed for CD25 expression by qPCR (left) and flow cytometry (right). 
Results are expressed as a percentage of RDM control and represent mean ± SD from 
three (qPCR) or five (flow cytometry) experiments. Asterisk (*): P < 0.05 compared with 
RDM control. B, expression of CD25 mRNA levels (left)  and C D 25 surface  
(right) in KU812 cells after incubation in medium (control) or pimozide (1, 5, and 10 
µmol/L) at 37°C for 24 hours. mRNA levels were quantified by qPCR, and surface 
expression by flow cytometry. Results are expressed as a percentage of ABL (qPCR) or 
percentage of medium control (flow cytometry), and represent the mean ± SD from five 
(qPCR) and four (flow cytometry) experiments. Asterisk (*): P < 0.05 compared with 
untreated cells (control). C, flow cytometric evaluation of CD25 expression on KU812 
cells after incubation in control medium or with the MEK inhibitors PD0325901 or 
RDEA119 (each 0.1–3 µmol/L) at 37°C for 24 hours. Results are expressed as a 
percentage of control and represent the mean ± SD from 3 experiments. Asterisk (*): P < 
0.05 compared with untreated cells (control). D, CD25 expression on KU812 cells after 
incubation in control medium, BEZ235, RAD001, or LY294002 (each 0.03–3 µmol/L) at 
37°C for 24 hours. Results represent the mean ± SD from three independent experiments. 
Asterisk (*): P < 0.05 compared with untreated cells (control).  
 
Figure 3  
Expression of CD25 on LSCs is dependent on STAT5 activity 
A, CD25 expression on CD34+/ CD38− LSCs was analyzed by flow cytometry after 
incubation in control medium, pimozide (10 or 50 µmol/L), or DMSO at 37°C for 24 
hours. Results show CD25 expression (median fluorescence intensity) on CD34+/CD38− 
LSCs as a percentage of control and represent the mean ± SD from three independent 
experiments. Asterisk (*): P < 0.05 compared with untreated cells (control). B, CD25 
expression on CD34+/CD38− LSCs after incubation in control medium, BEZ235, or 
RAD001 (each 1 µmol/L) at 37°C for 24 hours. Results show CD25 expression on 
CD34+/CD38− LSCs as a percentage of control and represent the mean ± SD from five 
independent experiments. C, expression of pSTAT5 (top) and CD25 (bottom) in KU812 
cells after incubation in control medium or TKIs (imatinib, nilotinib, ponatinib, each 
0.01–1 µmol/L) at 37°C for 4 hours (pSTAT5) or 24 hours (CD25). Results are expressed 
as staining index (SI; pSTAT5) or as a percentage of control (CD25), and represent the 
mean ± SD from at least three independent experiments. Asterisk (*): P < 0.05 compared 
with untreated cells (control). D, CD25 expression on CD34+/CD38− LSCs after 
incubation in control medium or TKIs (imatinib, nilotinib, or ponatinib, each 1 µmol/L) 
at 37°C for 24 hours. Results show CD25 expression on CD34+/CD38− LSCs as a 
percentage of medium control and represent the mean ± SD of five independent 
experiments. Asterisk (*): P < 0.05 compared with untreated cells. E, expression of 
pSTAT5 in CD34+/CD38− LSCs after incubation in control medium, BEZ235, RAD001 
(left), or TKIs (imatinib, nilotinib, ponatinib, 1 µmol/L each; right) at 37°C for 4 hours. 
Results represent the mean ± SD from five independent experiments.  
 
Figure 4 
Infection of STAT5A/B is followed by upregulation of CD25 in mouse LSK cells 
CD25 expression in Lin−/Sca-1+/Kit+ LSK cells after infection of murine C57Bl/6 BM 
cells with retroviral constructs encoding p210BCR/ABL1 (red bars), STAT5A/GFP (left, 
green bar) or STAT5B/GFP (right, green bar), or combinations of p210BCR/ABL1 and 
STAT5/GFP isoforms (blue bars). BM cells were infected as described in the text. 
Expression of CD25 on LSK cells was analyzed by multicolor flow cytometry using an 
antibody against CD25. Results are expressed as median fluorescence intensity (CD25 
expression) and represent the  m ean ± SD from five independent experiments. Asterisk 
(*) indicates P < 0.05 compared with p210BCR/ABL1-infected cells.  
 
Figure 5 
Evaluation of CD25 as a functional target on CML cells 
A, CD25 shRNA–transduced cells (shRNA clones #2, #1, #5 as indicated) were mixed 
1:1 with KU812 cells transduced with an RDM shRNA and cultured at 37°C. Expression 
of CD25+ cells was analyzed 3 times a week by flow cytometry using the PE-conjugated 
mAB 2A3 against CD25. Results are expressed as a percentage of CD25+ cells and 
represent the mean ± SD from at least 4 independent experiments. Asterisk (*) indicates P 
< 0.05 compared with CD25 expression on day 0. B, NSG mice were injected with CD25 
shRNA (clone #2) or RDM shRNA–transduced KU812 cells (5 mice/group). After 6 
weeks, NSG mice were analyzed for engraftment of CD44+ cells (expressed as %) in the 
BM, PB, and spleen by flow cytometry using an antibody against CD44 (top). The spleen 
weight, spleen size, and white blood count (WBC) are shown in the bottom plots. Results 
represent the mean ± SD from five mice per group. Asterisk (*): P < 0.05 compared with 
control mice. The images in the very right plots show the spleen size of NSG mice (#1–5: 
NSG mice injected with KU812 cells transduced with RDM shRNA; #6–9: NSG mice 
injected with KU812 cells transduced with CD25 shRNA). C, primary CD34+ 
stem/progenitor cells from 2 patients with CML CP were transduced with a CD25 shRNA 
(clone #2) or an RDM control shRNA. After 24 hours (recovery time), 3H-thymidine 
uptake was measured in highly enriched (sorted for mCherry) transduced cells. Results 
are expressed as a percentage of control (3H-thymidine uptake in RDM shRNA–
transduced cells = 100%) in three independent experiments (one experiment with cells 
from patient #51 and two experiments with cells from patient #50).  
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Supplementary Data to Manuscript: 
 
Identification of CD25 as STAT5-Dependent Growth-Regulator of 
Leukemic Stem Cells in Ph+ CML (Sadovnik et al.) 
 
 
Methods 
 
Reagents 
Pimozide, polybrene and RNase I were purchased from Sigma Aldrich (San Louis, 
MO, USA) and RDEA119 and PD0325901 from ChemieTek (Indianapolis, IN, USA). 
Imatinib, nilotinib and BEZ235 were kindly provided by Dr.E.Buchdunger and 
Dr.P.W.Manley (Novartis, Basel, Switzerland). Ponatinib and RAD001 (everolimus) 
were purchased from Selleck Chemicals (Houston, TX, USA) and LY294002 from 
Merck Millipore (Billerica, MA, USA). Stock solutions of drugs were prepared by 
dissolving in dimethyl-sulfoxide (DMSO) (Merck, Darmstadt, Germany). RPMI 1640 
medium, Dulbecco’s modified eagle medium (DMEM), fetal calf serum (FCS), and 
puromycin were purchased from PAA Laboratories (Pasching, Austria), 3H-thymidine 
from Amersham (Buckinghamshire, United Kingdom), propidium iodide (PI) from 
eBioscience (San Diego, CA, USA), recombinant human (rh) interleukin-2 (IL-2) from 
R&D Systems (Minneapolis, MN, USA) or ImmunoTools (Friesoythe, Germany), rh 
IL-3 and rh IL-6 from Novartis (Vienna, Austria), rh stem cell factor (SCF) from 
Peprotech (Rocky Hill, NJ, USA), rh thrombopoietin (TPO) and rh Flt3/Flk-2 ligand 
(FL) from Sigma (St. Louis, MO, USA), and recombinant murine IL-3, murine IL-6 
and murine SCF from R&D Systems (Minneapolis, USA). Stem Span medium, 
Myelocult H5100 medium, and Methocult H4434 medium (medium supplemented 
with methylcellulose and cytokines) were purchased from StemCell technologies 
(Vancouver, Canada). Stem Span medium was supplemented with rh IL-3 (50 ng/ml), 
rh IL-6 (50 ng/ml), rh SCF (50 ng/ml), rh TPO (25 ng/ml) and rh FL (5 ng/ml). A 
characterization of monoclonal antibodies (mAb) used in our flow cytometry 
experiments is provided in Supplementary Table S1. 
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Patients, diagnostic evaluation and follow-up examinations 
A total number of 63 patients with CML (32 females, 31 males) were examined. The 
median age was 54.04 years (range: 18-86 years). Diagnoses and the phase of CML 
were established according to the classification provided by the World Health 
Organization (WHO) (1). Prognostication at diagnosis and risk-stratification were 
performed according to the Sokal Score, Hasford Score, and EUTOS Score (2-4). 
Peripheral blood (PB) and/or bone marrow (BM) cells (iliac crest or sternum) were 
collected at diagnosis as well as in the follow-up. Karyotyping was performed at 
diagnosis and in defined time-intervals (3-month-intervals in the first year; and in 3-12 
month-intervals after the first year) following the recommendations of the European 
Leukemia Net (ELN) (5,6). BCR/ABL1 mRNA levels were determined in PB cells 
using ABL as a reference gene and the International Scale (IS) for standardized 
quantification (7-9). BCR/ABL1 was measured in 3-12 month-intervals. The patients´ 
characteristics are shown in Supplementary Table S2. Of the 63 patients examined, 52 
had chronic phase (CP) CML, 3 accelerated phase (AP) CML, and 8 were suffering 
from blast phase (BP) of CML (Supplementary Table S2). Patients were treated with 
imatinib (400 mg daily per os) and other tyrosine kinase inhibitors (TKI) according to 
available guidelines (5,6). In case of resistance or intolerance against imatinib, patients 
received a second-generation TKI (nilotinib or dasatinib). Hydroxyurea was used on 
demand for cytoreduction. All patients provided written informed consent before PB 
or BM samples were collected. The control patients´ cohorts are shown in 
Supplementary Table S3A (normal BM), Supplementary Table S3B (idiopathic 
cytopenia), Supplementary Table S3C (systemic mastocytosis) and Supplementary 
Table S3D (myeloproliferative neoplasm).  All studies, including storage of cells, drug 
incubation experiments and the examination of LSCs were approved by the local 
ethics committee of the Medical University of Vienna. 
 
Cell sampling and storage 
A total number of 180 cell samples, including 124 CML samples and 56 control 
samples were analyzed. Control samples were from patients with reactive or normal 
BM (Non-Hodgkins´s or Hodgkin´s Lymphoma without BM involvement, n=14; 
monoclonal gammopathy of unknown significance, n=1; solid tumors without BM 
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involvement, n=2; suspected mastocytosis, n=7), idiopathic cytopenia of undetermined 
significance, ICUS (n=14), myeloproliferative neoplasms, MPN (n=6), and indolent 
systemic mastocytosis, ISM (n=7). The patients´ characteristics are shown in 
Supplementary Table S3A-S3D. Stabilizer-free heparin (Biochrom AG, Berlin, 
Germany) was used as anticoagulant. Freshly obtained samples (PB, BM) were 
subjected to flow cytometry analysis and isolation of mononuclear cells (MNCs) using 
Ficoll gradient centrifugation. Isolated MNCs were either used immediately or were 
frozen in liquid nitrogen until used. Frozen MNCs were thawed using DNAse type I, 
100 U/mL (Sigma Aldrich, St. Louis, MO, USA) to prevent cell clumping.  
 
Flow cytometry analysis 
Phenotyping of CD34+/CD45+/CD38─ stem cells (SCs) and CD34+/CD45+/CD38+ 
progenitor cells was performed in 54 patients with CML. Whole BM and/or PB 
samples or MNCs were used (n=116). Multicolor flow cytometry was performed as 
described (10,11) using fluorochrome-conjugated mAb shown in Supplementary Table 
S1. Flow cytometry was performed on a FACSCalibur (Becton Dickinson, San José, 
CA, USA). All staining reactions were controlled by isotype-matched control 
antibodies and expressed as percentage of positive cells. In a select group of healthy 
(non-leukemic) controls (n=5) and CML patients (n=5), expression of CD25, CD122 
and CD132 on CD19+ B cells, CD3+ T cells, CD14+ monocytes, and CD123+ basophils 
(lineage controls) was analyzed by multicolor flow cytometry. Results of these 
analyses are shown in Table 2. In addition, we analyzed the expression of CD25 on 
CD34+/CD38─ SCs in the follow-up of 17 CML patients treated with imatinib (400 mg 
per os daily, n=14), nilotinib (2 x 400 mg per os daily; n=2) or dasatinib (100 mg per 
os daily, n=1) according to the guidelines of the ELN (5,6). In 4 patients with CML, 
LSCs (CD34+/CD38─) and progenitor cells (CD34+/CD38+) were purified to 
homogeneity by cell sorting on a FACSAria (Becton Dickinson) as described (11). In 
a separate series of experiments, CD34+/CD38─/CD25+ LSCs and CD34+/CD38─/ 
CD25─ (residual normal) stem cells were sorted from MNC of 5 CML patients by flow 
cytometry (for FISH analyses and LTC-IC). For transfection studies, CD34+ CML 
stem- and progenitor cells were purified by MACS technology from MNC in 2 
patients (CML CP) as described (12). Enriched CD34+ cells (23-30% of the cells 
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expressed CD25) were transduced with a short hairpin RNA (shRNA) against CD25 
(clone #2) or a random (RDM) control shRNA. Four days after transduction, shRNA-
transfected cells were enriched by cell sorting (sorted for the mCherry tag of the 
shRNA construct) on a FACSAria before being analyzed for their proliferative 
potential. To evaluate potential mechanisms underlying CD25 expression in CML 
cells, KU812 cells were incubated in control medium or in medium supplemented with 
imatinib, nilotinib, ponatinib, pimozide, PD0325901, RDEA119, BEZ235, RAD001, 
or LY294002 (0.01-3 µM) at 37°C for 24 hours. In addition, we incubated K562, 
imatinib-resistant K562 cells (K562-R), and KCL-22 cells with BEZ235, RAD001, 
and LY294002 (0.01-3 µM) at 37°C for 24 hours. After incubation, cells were stained 
with PE-conjugated mAb 2A3 against CD25 (15 minutes) and analyzed by flow 
cytometry. To further evaluate the effects of various drugs on CD25 expression, Ba/F3 
cells expressing various BCR/ABL1 mutants were incubated in medium supplemented 
with imatinib, nilotinib, ponatinib or BEZ235 (0.01-5 µM) at 37°C for 24 hours. After 
incubation, cells were stained with a rat anti-mouse PE-conjugated mAb 3C7 against 
CD25 (15 minutes) and analyzed by flow cytometry. For staining of cytoplasmic 
molecules, KU812 cells or CML MNCs were incubated in control medium or in 
medium supplemented with various compounds at 37°C for 4 hours. After incubation, 
CML MNCs were stained with mAb HI30 against CD45, mAb 581 against CD34 and 
mAb HIT2 against CD38 (15 minutes). Then CML cells were fixed in 4% 
formaldehyde (15 minutes) and permeabilized in methanol (-20°C, 15 minutes). 
Thereafter, CML cells were incubated with mAb 47 (pY694) against pSTAT5 (30 
minutes) and analyzed on a FACSCanto (Becton Dickinson). KU812 cells were first 
fixed in formaldehyde and permeabilized in methanol (-20°C) and then stained with 
mAb 47 against pSTAT5 and analyzed on a FACSCalibur. For cell cycle studies, 
KU812 cells were either transduced with a control RDM shRNA or a specific CD25 
shRNA (clone #2). Cells were then resuspended in 300 µL permeabilization buffer 
(0.1% Na-acetate and 0.1% Triton X-100) and RNase I (1:100). Thereafter, PI was 
added and cell cycle distribution was analyzed on a FACSCalibur. For flow cytometric 
determination of apoptosis, cells were examined as described (13). In brief, cells were 
fixed in 4% formaldehyde and permeabilized in methanol as reported. Thereafter, cells 
were washed and incubated with a PE-conjugated mAb C92-605 against active 
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caspase-3 for 30 minutes. After washing, cells were analyzed on a FACSCalibur, and 
the percentage of apoptotic (active caspase-3+) cells was determined. 
 
Measurement of 3H-thymidine uptake in CML cells 
To determine the growth-inhibitory effects of various drugs, KU812, K562, Ba/F3 
cells (BCR/ABL1 wild type and various BCR/ABL1 mutants) (1x104 cells/well), or 
primary CML MNCs (1x105 cells/well) were incubated in control medium or in 
various concentrations of BEZ235 (0.001-10 µM), imatinib (0.01-1 µM), nilotinib 
(0.0001-1 µM), or ponatinib (0. 05-1 nM) alone or in combination in 96-well culture 
plates (TPP, Trasadingen, Switzerland) at 37°C for 48 hours. The effects of IL-2 
(either direct incubation or pre-incubation of cells with IL-2: 100-2,000 ng/ml) on 
proliferation were tested in KU812 cells, K562 cells as well as in primary CML MNCs 
(5 patients). In another set of experiments, primary CD34+ cells (purity >98%) from 2 
patients with CP CML (23-30% CD25+ cells) were transduced with a specific CD25 
shRNA (clone #2) or a RDM control shRNA and cultured in Stem Span medium 
supplemented with cytokines. After 4 days, shRNA-transduced cells were enriched by 
cell sorting (mCherry+) and incubated for 24 hours (recovery time after sorting). After 
incubation of cells with drugs, cytokines, or shRNA, 0.5 µCi 3H-thymidine was added 
(37°C, 16 hours). Cells were then harvested on filter membranes (Packard 
Biosciences, Meriden, CT) in a Filtermate 196 harvester (Packard Bioscience). Filters 
were air-dried, and the bound radioactivity was counted in a ß-counter (Top-count 
NXT, Packard Bioscience). All experiments were performed in triplicates. 
 
Analysis of STAT5 expression by Western blotting (WB) 
Untransduced KU812 cells and KU812 cells transduced with STAT5 shRNA or RDM 
shRNA (see text in main manuscript) were analyzed by WB as described (14) using a 
mAb against STAT5 (clone 89/STAT5, BD Bioscience, San Jose, CA) and a 
polyclonal antibody against Akt (Cell Signaling Technology, Danvers, MA). 
Antibody-reactivity was made visible by donkey-anti-rabbit IgG or sheep-anti-mouse 
IgG (both from GE Healthcare, Buckinghamshire, UK) and Lumingen PS-3 detection 
reagent (Thermo Scientific, Rockford, IL). 
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Gene Array Analyses 
To define differences in mRNA expression patterns in KU812 cells transduced with 
RDM shRNA or a shRNA against CD25 (clone #2), gene array analyses were 
performed. Total RNA was extracted from CML cells using RNeasy Micro-Kit 
(Qiagen) and used (150 ng total RNA) for Gene Chip analyses. Preparation of 
terminal-labeled cRNA, hybridization to genome-wide human Gene 2.0 ST Arrays 
(Affymetrix, Santa Clara, CA, USA) and scanning of arrays were carried out 
according to the manufacturer's protocols (https://www.affymetrix.com). Robust 
Multichip Average (RMA) signal extraction and normalization were performed using 
GeneChip Expression Console Version 1.3.1. Differences in mRNA expression levels 
were calculated as normalized fluorescence signal ratio of KU812 CD25 shRNA cells 
versus KU812 RDM shRNA cells. A complete data set is available at Gene Expression 
Omnibus 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=orotekeollgdduf&acc=GSE603
15. In addition, this data set was analyzed for enriched pathways following CD25 
depletion by shRNA (compared to RDM shRNA). Genes which are at least 2 fold 
regulated were included in this analysis using www.pantherdb.org. To determine 
statistical differences in enriched pathways, statistical analysis and Bonferroni 
correction were applied essentially as described (15). 
 
Quantitative PCR (qPCR) and cytogenetics 
To confirm expression of CD25, CD122, and CD132 mRNA in KU812 cells and CML 
LSCs, qPCR was performed as reported (11) using the following primers: CD25 
forward: GGACTGCTCACGTTCATCATGG, CD25 reverse: GCTTTGAATGTGG 
CGTGTGG; CD122 forward: GGGCTCTGCAGGACACTTCC, CD122 reverse: 
GGAGCAGCTCACAGGTTTGG; CD132 forward: TTGGAGCACTTGGTGCA 
GTA, CD132 reverse: CCATCCACACTAGGCAAGGA. Total RNA was extracted 
from KU812 cells, sorted CD34+/CD38− LSCs, CD34+/CD38+ progenitor cells, CD34− 
cells, and MNCs from four patients with CML using the RNeasy Micro Kit (Qiagen, 
Hilden, Germany). RNA was also extracted from pooled colonies obtained from LTC-
IC cultures (grown from CD34+/CD38─/CD25+ LSCs and CD34+/CD38─/CD25─ stem 
cells). BCR/ABL1 was detected using the following primers: BCR/ABL1 forward: 
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TCCGCTGACCATCAATAAGGA, BCR/ABL1 reverse: CACTCAGACCCTGAGG 
CTCAA. ABL served as a reference gene: ABL forward: TGTATGATTTTGTGGC 
CAGTGGAG, ABL reverse: GCCTAAGACCCGGAGCTTTTCA. Conventional 
cytogenetics and FISH were performed according to published protocols (16). 
Conventional cytogenetics was performed in all patients with CML at diagnosis and in 
the follow-up (first year: 3 month intervals; and after the first year in 3-12 month-
intervals and in case of suspected progression/relapse). At least 20 metaphases were 
examined whenever possible. Karyotypes were reported according to available 
guidelines (16). Results were expressed as percentage of Ph-chromosome-positive 
metaphases. In case of questionable results or poor growth, fluorescence in situ 
hybridization (FISH) analysis was performed. FISH was also performed to confirm the 
presence of BCR/ABL1 in sorted CD25+ and CD25− fractions of CD34+/CD38− stem 
cells in three patients with CML. A summary of FISH results is shown in 
Supplementary Table S4. FISH was performed on cytospin slides using a triple color-
staining approach with one probe specific for ABL1 (red) and two probes (green and 
blue) specific for BCR (Kreatech, Amsterdam, The Netherlands) as described (16).  
 
Long term culture-initiating cell (LTC-IC) assay 
LTC-ICs were prepared using highly purified, sorted CD34+/CD38─/CD25+ LSCs and 
CD34+/CD38─/CD25─ (presumably normal) stem cells in 2 patients with CP CML and 
irradiated (60 Gy) murine M2-10B4 feeder cells (ATCC, Manassas, VA, USA) 
essentially as described (12). Suspension cultures were maintained in Myelocult 
H5100 Medium according to the manufacturer´s protocol (StemCell Technologies). 
Before being cultured in the LTC-IC assay, CML MNCs were separated (sorted) into 
CD34+/CD38─/CD25+ LSCs and CD34+/CD38─/CD25─ stem cells from the same 
samples (patients) and cultured separately in the LTC-IC assay (1,000 cells/mL/well). 
After 3 weeks in liquid culture, cells were recovered and transferred to methylcellulose 
(CFU) cultures (Methocult H4434) prepared according to the manufacturer´s protocol 
(StemCell Technologies). CFU-GM and BFU-E formation was assessed on day 14 
using an inverted microscope as described (12). The percentage of BCR/ABL1 mRNA 
in isolated, pooled, CFU-GM colonies (10 colonies/pool) was determined by qPCR. 
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 Supplementary Tables and Figures 
 
Supplementary Table S1 
 
Specification of monoclonal antibodies (mAb) used in this study 
CD   antigen   clone  isotype  conjugate reactivity company* 
n.c.  isotype control  MOPC-21 mouse, IgG1      PE  human  BD Biosciences 
n.c.  isotype control  20102  mouse, IgG2A      PE  human  R&D Systems 
n.c.  isotype control  133303  mouse, IgG2B      PE  human  R&D Systems 
n.c.  isotype control  MOPC-21 mouse, IgG1      Alexa647 human  BD Biosciences 
n.c.  isotype control  MOPC-21 mouse, IgG1      APC human  BD Biosciences 
CD3  TcR   UCHT1 mouse, IgG1      APC human  BD Biosciences 
CD14  LPSR   TÜK4  mouse, IgG2A      FITC human  Dako 
CD19  B4   4G7  mouse, IgG1      FITC human  BD Biosciences 
CD25  IL-2RA  2A3  mouse, IgG1      PE  human  BD Biosciences 
CD25  IL-2RA  BC96  mouse IgG1      PE  human  eBioscience 
CD25  IL-2RA  BC96  mouse IgG1     APC  human  BioLegend 
CD26  DPPIV   M-A261 mouse, IgG1      PE  human  BD Biosciences 
CD33  Siglec-3  WM53  mouse, IgG1      PE  human  BD Biosciences 
CD34  HPCA-1  581  mouse, IgG1      FITC human  BD Biosciences 
CD34   HPCA-1  581  mouse, IgG1      PE  human  BD Biosciences 
CD38  T10   HIT2  mouse, IgG1      APC human  BD Biosciences 
CD44  Pgp1   515  mouse, IgG1      PE  human  BD Biosciences 
CD45  LCA   2D1  mouse, IgG1      PerCP human  BD Biosciences 
CD45  LCA   HI30  mouse, IgG1      V500 human  BD Biosciences 
CD52  Campath-1  HI186  mouse, IgG2B      PE  human  BioLegend 
CD117  SCFR/KIT  104D2  mouse, IgG1      PE  human  BD Biosciences 
CD122  IL-2RB  Mik-β3  mouse, IgG1      PE  human   BD Biosciences 
CD123  IL-3RA  AC145  mouse, IgG2A      APC human  Miltenyi Biotec 
CD132  IL-2RG  AG184  mouse, IgG1      PE  human  BD Biosciences 
n.c.  IL-1RAP  89412  mouse, IgG1      PE  human  R&D Systems 
n.c.  pSTAT5  47(pY694) mouse, IgG1      Alexa647 human  BD Biosciences 
n.c  caspase-3  C92-605 mouse, IgG1      PE  human  BD Biosciences 
n.c.  isotype control  A95-1  rat, IgG2b      PE  mouse  BD Pharmingen 
CD25  IL-2RA  3C7  rat, IgG      PE  mouse  BD Pharmingen 
CD25  IL-2RA  PC61  rat, IgG      APC mouse  BD Pharmingen 
n.c.  Sca-1 or Ly6A/E D7  rat, IgG      PE Cy7 mouse  BD Pharmingen 
CD117  c-kit   2B8  rat, IgG      PE Cy5 mouse  eBioscience  
CD11b  integrin alpha-M M1/70  rat, IgG      biotin mouse  BD Biosciences 
CD3e  CD3e   145-2C11 rat, IgG      biotin mouse  BD Biosciences 
CD45R  B220   RA3-6B2 rat, IgG      biotin mouse  BD Biosciences 
n.c.  Ter119   Ter119  rat, IgG      biotin mouse  BD Biosciences 
n.c.  GR-1 or LygC/Ly6G RB6-8C5  rat, IgG      biotin mouse  BD Biosciences 
------------------------------------------------------------------------------------------------------------------------------------------------------ 
CD, cluster of differentiation; PE, phycoerythrin; FITC, fluorescein isothiocyanate; PerCP, peridinin chlorophyll 
protein; APC, allophycocyanin; Cy, cyanine dye; Alexa647, alexa fluor 647; n.c., not (yet) clustered; BD, 
Becton Dickinson; Ig, immunoglobulin; TcR, T cell receptor; LPSR, lipopolysaccharide-related antigen; IL-
2RA, interleukin-2 receptor alpha chain; DPPIV, dipeptidyl-peptidase IV; HPCA-1, human precursor cell 
antigen-1; LCA, leukocyte common antigen; SCFR, stem cell factor receptor; IL-2RB, interleukin-2 receptor 
beta chain; IL-3RA, interleukin-3 receptor alpha chain; IL-2RG, interleukin-2 receptor gamma chain; IL-1RAP, 
interleukin-1 receptor accessory protein; p, phosphorylated; STAT5, signal transducer and activator of 
transcription 5. 
Company Location: BD Bioscience, San José, CA, USA; R&D Systems, Minneapolis, MN, USA; Dako, 
Glostrup, Denmark; eBioscience, San Diego, CA, USA; Miltenyi Biotec, Bergisch Gladbach, Germany; 
BioLegend, San Diego, CA, USA.  
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Supplementary Table S2 
 
Patients´ characteristics – chronic myeloid leukemia (CML) 
No diagnosis karyotype 
age gender WBC Hb Plt basophil PB blasts PB blasts BM BCR/ABL1 Samples used at D/FU 
(months after therapy; TKI) MR/CR (yrs) (m/f) (G/L) (g/dL) (G/L) (%) (%) (%) (%) 
1 CML CP 46,XY,t(9;22) 49 m 232.75 9.3 1062 6 3 1 39.269 D n.a. 
2 CML CP 46,XX,t(9;22) 42 f 181.87 14.1 148 4 1 2 67.485 D n.a. 
2 CML FU 46,XX 44 f 6.43 12.5 200 0 0 1 0.188 FU (24 months; IM) NMR/CCyR 
3 CML CP 46,XY,t(9;22) 37 m 396 9.3 225 4 5 3 18.44 D n.a. 
3 CML FU 46,XY 45 m 6.54 14.2 204 1 0 2 0.07 FU (139 months; IM) MMR/CCyR 
4 CML CP 46,XX,t(9;22) 22 f 26.58 13.4 354 5 0 1 60.051 D n.a. 
4 CML FU 46,XX 23 f 4.48 11 210 0 0 1 0.076 FU (14 months; IM) MMR/CCyR 
5 CML CP 46,XY,t(9;22) 56 m 271.49 9.2 607 8 2 2 43.205 D n.a. 
5 CML FU 46,XY 57 m 4.58 11.8 235 2 0 1 0.116 FU (12 months; IM) NMR/CCyR 
6 CML CP 46,XX,t(9;22) 35 f 193.84 11.5 222 4 1 2 100 D n.a. 
6 CML FU 46,XX 38 f 2.79 12.6 122 0 0 1 0.006 FU (45 months; IM) MMR/CCyR 
7 CML CP 46,XY,t(9;22) 28 m 96.83 12.9 174 2 1 1 58.88 D n.a. 
7 CML FU 46,XY,t(9;22) 33 m 3.39 12.8 135 0 0 1 0.002 FU (64 months; IM) MMR/PCyR 
8 CML CP 46,XY,t(9;22) 85 m 45.74 12.4 330 2 1 2 37.752 D n.a. 
9 CML CP 46,XX,t(9;22) 62 f 43.52 11.7 265 19 1 4 13.62 D n.a. 
9 CML FU 46,XX 70 f 4.76 12.2 232 0 0 1 0 FU (98 months; IM) CMR/CCyR 
10 CML CP 46,XX,t(9;22) 46 f 47 11.1 591 2 0 1 80 D n.a. 
10 CML FU 46,XX 50 f 6.2 13.3 234 0 0 2 0.01 FU (57 months; IM, NIL) MMR/CCyR 
11 CML CP 46,XY,t(9;22) 33 m 190.69 9.7 750 4 3 8 38.867 D n.a. 
              
              
 10 
No diagnosis karyotype 
age gender WBC Hb Plt basophil PB blasts PB blasts BM BCR/ABL1 Samples used at D/FU 
(months after therapy; TKI) MR/CR (yrs) (m/f) (G/L) (g/dL) (G/L) (%) (%) (%) (%) 
12 CML CP 46,XX,t(9;22) 67 f 37.6 10.5 1375 3 1 4 100 D n.a. 
12 CML FU 46,XX 69 f 7.05 12.2 225 1 0 1 0 FU (20 months; IM, NIL) CMR/CCyR 
13 CML CP 46,XY,t(9;22) 62 m 46.54 11.8 419 4 1 2 51.478 D n.a. 
13 CML FU 46,XY 63 m 5.66 12.6 198 1 0 1 0.076 FU (11 months; IM) MMR/CCyR 
14 CML CP 46,XX,t(9;22) 84 f 67.64 12.8 305 2 0 1 42.294 D n.a. 
15 CML CP 46,XY,t(9;22) 56 m 48.12 13.9 217 1 0 1 67 D n.a. 
15 CML FU 46,XY 60 m 8.15 11.4 268 0 0 2 0.21 FU (43 months; IM) NMR/CCyR 
16 CML CP 46,XX,t(9;22) 67 f 332.22 10.3 568 4 4 4 98 D n.a. 
17 CML CP 46,XY,t(9;22) 47 m 55.74 13.9 250 1 1 3 45.667 D n.a. 
17 CML FU 46,XY 50 m 4.94 13.7 176 1 0 1 0.003 FU (35 months; IM) MMR/CCyR 
18 CML CP 46,XY,t(9;22) 51 m 174.2 11.6 275 1 1 1 69.884 D n.a. 
18 CML FU 46,XY 52 m 5.5 13.2 184 1 0 2 0.627 FU (9 months; IM) NMR/CCyR 
19 CML CP 46,XY,t(2;10),t(9;22) 72 m 112.5 11.9 394 13 6 4 79 D n.a. 
20 CML CP 46,XX,t(9;22) 45 f 184 10.1 700 1 1 1 45.037 D n.a. 
20 CML FU 46,XX 46 f 3.36 10.8 148 0 0 1 0.027 FU (50 months, IM) MMR/CCyR 
21 CML CP 46,XX,t(9;22) 74 f 34.22 12.8 911 6 0 1 72.343 D n.a. 
22 CML CP 46,XX,t(9;22) 22 f 230.57 10.4 720 5 1 1 50.089 D n.a. 
23 CML CP 46,XY,t(9;22) 64 m 23.9 13.3 164 1 0 1 61.3 D n.a. 
24 CML CP complex, t(9;22) 54 m 290.43 12.4 441 3 2 2 63.192 D n.a. 
24 CML FU 46,XY 57 m 5.91 13.1 319 1 0 1 0.029 FU (36 months; DAS) MMR/CCyR 
25 CML CP 46,XY,t(9;22) 65 m 38.39 11.8 311 5 0 1 57.164 D n.a. 
26 CML CP 46,XY,t(9;22) 65 m 30.58 15.2 216 3 0 1 40 D n.a. 
26 CML FU 46,XY 70 m 7.2 13.4 227 0 0 1 0.006 FU (63 months; IM) MMR/CCyR 
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No diagnosis karyotype 
age gender WBC Hb Plt basophil PB blasts PB blasts BM BCR/ABL1 Samples used at D/FU 
(months after therapy; TKI) MR/CR (yrs) (m/f) (G/L) (g/dL) (G/L) (%) (%) (%) (%) 
27 CML CP 46,XX,t(9;22) 42 f 61.2 13.5 319 3 0 1 92.56 D n.a. 
27 CML FU 46,XX 48 f 4.89 11.3 194 1 0 1 0.008 FU (61 months; IM) MMR/CCyR 
28 CML CP 46,XY,t(9;22) 74 m 48.41 13.1 321 1 1 1 22.897 D n.a. 
29 CML CP n.t. 43 f 113.7 12.3 514 5 3 2 34.27 D n.a. 
30 CML CP 46,XY,t(9;22) 65 m 27.75 14.7 114 7 1 1 34.055 D n.a. 
31 CML CP 46,XX,t(9;22) 68 f 40.22 12.1 413 5 n.t. 2 21.851 D n.a. 
32 CML CP 46,XY,t(9;22) 71 m 49.8 14.1 320 4 1 1 38.655 D n.a. 
33 CML CP 46,XY* 54 m 32.8 12.7 434 2 n.t. 3 76.909 D n.a. 
34 CML CP 46,XY,t(9;22) 18 m 175.8 8.7 282 3 2 1 51.578 D n.a. 
35 CML CP 46,XY,t(9;22) 71 m 179.1 11.1 83 4 1 n.t. 4.507 D n.a. 
36 CML CP 46,XY,t(9;22) 65 m 273.59 7.7 470 8 10 6 78.903 D n.a. 
37 CML CP 46,XX* 67 f 46.7 10.6 313 n.t. n.t. 2 n.t. D n.a. 
38 CML CP 46,XX,t(9;22) 57 f 39.11 12.1 150 n.t. n.t. 1 38.662 D n.a. 
39 CML CP n.t. 73 f 10.4 4.4 942 n.t. n.t. n.t. 47.979 D n.a. 
40 CML CP 46,XX,t(9;22) 27 f 348 9.6 213 7 6 <5 n.t. D n.a. 
41 CML CP 46,XX,t(9;22) 27 f 415 7 406 2 1 <5 n.t. D n.a. 
42 CML CP 46,XY,t(9;22) 40 m 320 10.4 507 4 2 <5 n.t. D n.a. 
43 CML CP 46,XX,t(9;22) 57 f 365.6 8.8 516 5 8 <5 n.t. D n.a. 
44 CML CP 46,XY,t(9;22) 50 m 282 10.8 632 9 5 <5 n.t. D n.a. 
45 CML CP 46,XX,t(9;22) 51 f 99.8 10,5 202 2 1 <5 n.t. D n.a. 
46 CML CP 46,XX,t(9;22) 51 f 93.6 11.5 568 9 4 <5 n.t. D n.a. 
47 CML CP 46,XY,t(9;22) 62 m 335 9 902 5 5 <5 n.t. D n.a. 
48 CML CP 46,XY,t(9;22) 55 m 40.9 13.9 889 10 n.t. n.t. 28.48 D  n.a. 
48 CML FU 46,XY 62 m 5.12 13.3 303 0 n.t. 1 n.t. FU ( 87 months, IM) n.t./CCyR 
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No diagnosis karyotype 
age gender WBC Hb Plt basophil PB blasts PB blasts BM BCR/ABL1 Samples used at D/FU 
(months after therapy; TKI) MR/CR (yrs) (m/f) (G/L) (g/dL) (G/L) (%) (%) (%) (%) 
49 CML CP 46,XX,t(9;22) 66 f 127.2 10.1 607 5 9 <5 n.t. D n.a. 
49 CML FU  TKI resistant n.t. 76 f 4.23 9.4 86 n.t. 1 2 52.29 FU (131 months, IM) NMR/n.t. 
50 CML CP 46,XX,t(9;22) 24 f 77 12.3 363 5 2 1 47,22 D n.a. 
50 CML CP 46,XX,t(9;22) 25 f 506.92 7.9 197 3 9 n.t. n.t. FU NMR/NR 
51 CML CP n.t. 46 f 570.5 7.5 342 3 1 2 57,54 D n.a. 
52 CML CP n.t. 68 f 97,83 10,9 11,2 6 1 1 51,63 D n.a. 
53 CML AP 46,XX,t(9;22) 27 f 178.3 10.2 626 15 7 5 71.765 D n.a. 
54 CML AP 46,XX,t(9;22) 86 f 230 8.9 783 4 11 3 100 D n.a. 
55 CML AP 46,XY,t(9;22),t(8;17) 39 m 190.9 11 347 15 3 2 56.38 D n.a. 
56 CML BP ly 46,XY,t(9;22) 72 m 20.35 10 12 0 69 80 86 D n.a. 
57 CML BP ly 45,XX,-7,t(9;22) 35 f 32.97 9.7 172 2 30 50 97.758 D n.a. 
58 CML BP ly 46,XX,t(9;22) 66 f 16.6 13.3 48 n.t. 80 100 62 D n.a. 
59 CML BP ly 46,XY,t(9;22) 72 m 104.43 9.8 73 0 46 36 87.593 D n.a. 
60 CML BP ly 46,XY,t(9;22) 38 m 137.35 7.3 29 n.t. 50 n.t. n.t. D n.a. 
61 CML BP my complex, t(9;22) 84 f 149.8 5.5 62 1 63 83 61.699 D n.a. 
62 CML BP my 46,XX,t(9;22) 60 f 94.4 10.9 45 1 35 75 38.806 D n.a. 
63 CML BP my 46,XY,t(9;22) 43 m 5.5 12.4 158 n.t. n.t. 25 48.16 D n.a. 
 
No, number; yrs, years; m, male; f, female; WBC, white blood count; Hb, hemoglobin; Plt, platelet count; PB, peripheral blood; BM, bone marrow; G/L, 
109 cells per liter; g/dL, gram per deciliter; CP, chronic phase; AP, accelerated phase; BP, blast phase; my, myeloid; ly, lympathic; D, diagnosis, FU, 
follow-up; IM, imatinib; NIL, nilotinib; DAS, dasatinib; MR/CR, molecular response/ cytogenetic response; CHR, complete hematologic response; 
CMR, complete molecular response; MMR, major molecular response; NMR, no molecular response; NR, no response; CCyR, complete cytogenetic 
response; n.t.; not tested; n.a., not applicable. *In these patients a cryptic translocation of BCR/ABL1 was detectable by FISH in leukemic cells. 
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Supplementary Table S3A  
Patients´ characteristics – normal/reactive BM 
No diagnosis age (yrs) 
gender 
(m/f) 
WBC 
(G/L) 
Hb 
(g/dL) 
Plt 
(G/L) 
blasts PB 
 (%) 
blasts BM 
 (%) 
1 NHL 70 m 3.6 10.2 189 0 2 
2 NHL 23 m 11.7 14.1 210 0 2 
3 NHL 71 m 13 14.7 108 0 1 
4 solid tumor 52 m 8 15 203 0 1 
5 suspected SM 23 m 6 14.4 165 0 1 
6 NHL 72 m 13.8 14.3 286 0 1 
7 NHL 40 m 5.5 14.6 247 0 1 
8 NHL 77 f 3.9 10.2 110 0 1 
9 NHL 28 m 5.2 16.9 198 0 2 
10 NHL 61 m 8.1 7.6 530 0 1 
11 solid tumor 27 f 9.1 13.8 354 0 1 
12 NHL 63 f 6.8 14.6 208 0 1 
13 Hodgkin 38 m 14.8 13.1 234 n.t. 2 
14 NHL 66 f 5.9 14.9 307 0 1 
15 Hodgkin 23 m 11.9 12.1 427 0 2 
16 NHL 58 f 5.1 12 230 0 2 
17 MGUS 52 m 7.2 15.3 219 0 1 
18 NHL 45 m 5.1 14.5 245 0 1 
19 suspected SM 32 m 4.3 15.2 278 0 1 
20 suspected SM 31 f 4.7 13.7 229 0 <5 
21 suspected SM 54 m 9.5 16 356 0 <5 
22 suspected SM 44 f 7.1 14.1 267 0 <5 
23 suspected SM 50 m 7.4 15.3 242 n.t. 1 
24 suspected SM 35 m 7.3 14.2 241 0 1 
 
No, number; yrs, years; m, male; f, female; WBC, white blood count; Hb, hemoglobin; Plt, 
platelet count; PB, peripheral blood; BM, bone marrow; G/L, 109 cells per liter; g/dL, gram 
per deciliter; NHL, Non Hodgkin’s lymphoma, MGUS, monoclonal gammopathy of 
undetermined significance; SM, systemic mastocytosis; n.t.; not tested. 
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Supplementary Table S3B  
Patients´ characteristics – idiopathic cytopenia of undetermined significance (ICUS) 
No diagnosis age (yrs) 
gender 
(m/f) 
WBC 
(G/L) 
Hb 
(g/dL) 
Plt 
(G/L) 
basophils PB 
(%) 
blasts PB 
 (%) 
blasts BM 
 (%) 
1 ICUS 82 f 7.4 11.8 82 0 0 1 
2 ICUS 37 f 2.7 11.6 196 2 0 0 
3 ICUS 56 f 1.6 11.6 25 0 0 1 
4 ICUS 69 m 2.4 10.6 1 2 0 1 
5 ICUS 79 m 3.4 13.2 89 1 0 1 
6 ICUS 44 f 4 10.8 189 2 0 1 
7 ICUS 64 m 3.7 9.8 67 1 0 1 
8 ICUS 62 m 5 8.4 94 0 0 2 
9 ICUS 34 f 2.5 13.7 159 1 0 1 
10 ICUS 68 f 2.5 13.8 189 1 0 2 
11 Haemolysis 42 m 15.7 7.8 259 2 1 1 
12 Agranulocytosis 47 m 1.7 10.6 399 2 0 2 
13 ICUS 60 m 1.5 10.9 45 0 0 2 
14 ICUS 53 f 3.2 11.3 173 0 0 1 
 
No, number; yrs, years; m, male; f, female; WBC, white blood count; Hb, hemoglobin; Plt, 
platelet count; PB, peripheral blood; BM, bone marrow; G/L, 109 cells per liter; g/dL, gram 
per deciliter; ICUS; idiopathic cytopenia of undetermined significance. 
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Supplementary Table S3C  
Patients´ characteristics – systemic mastocytosis 
No diagnosis age (yrs) 
gender 
(m/f) mutations karyotype 
WBC 
(G/L) 
Hb 
(g/dL) 
Plt 
(G/L) 
basophils PB 
(%) 
blasts PB 
 (%) 
blasts BM 
 (%) 
1 ISM 53 f KIT D816V 46,XX 9.7 13.6 263 0 0 1 
2 ISM 36 f KIT D816V 46,XX 5.1 13.6 193 0 0 1 
3 ISM 25 m KIT D816V 46,XY 7.5 15.1 223 1 0 2 
4 ISM 69 f none 46,XX 5.1 13.3 236 0 0 1 
5 ISM 63 f KIT D816V 46,XX  6 12.7 285 1 0 2 
6 ISM 25 f none n.t. 6.3 12.8 212 0 0 1 
7 ISM 56 m KIT D816V 46,XY 6.8 13.8 223 0 0 2 
 
No, number; yrs, years; m, male; f, female; WBC, white blood count; Hb, hemoglobin; Plt, platelet count; PB, peripheral blood; 
BM, bone marrow; G/L, 109 cells per liter; g/dL, gram per deciliter; ISM, indolent systemic mastocytosis; n.t., not tested. 
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Supplementary Table S3D  
Patients´ characteristics – myeloproliferative neoplasm 
No diagnosis age (yrs) 
gender 
(m/f) mutations karyotype WHO 
WBC 
(G/L) 
Hb 
(g/dL) 
Plt 
(G/L) 
basophils PB 
(%) 
blasts PB 
 (%) 
blasts BM 
 (%) 
1 MPN 70 m JAK2 V617F n.t. PMF 8.1 13.4 375 0 0 1 
2 MPN 67 f JAK2 V617F 46,XX ET 8.9 13.2 660 2 0 2 
3 MPN 48 m JAK2 V617F 46,XY ET 9 14.5 974 5 0 1 
4 MPN 61 m JAK2 V617F 46,XY PMF 8.7 8.7 138 1 0 1 
5 MPN 45 f JAK2 V617F 46,XX PMF 11.1 14.6 966 1 0 1 
6 MPN 21 f JAK2 V617F n.t. ET 8.7 13.5 605 2 0 2 
 
No, number; yrs, years; m, male; f, female; WHO, world health organisation; WBC, white blood count; Hb, hemoglobin; Plt, 
platelet count; PB, peripheral blood; BM, bone marrow; G/L, 109 cells per liter; g/dL, gram per deciliter; MPN; myeloproliferative 
neoplasm; PMF, primary myelofibrosis; ET, essential thrombocythemia; JAK, Janus kinase.  
 
 
 17 
Supplementary Table S4 
 
Detection of BCR/ABL1 in sorted CML cells by FISH 
---------------------------------------------------------------------------- 
Cell Population     % BCR/ABL1+ cells 
---------------------------------------------------------------------------- 
Patient #11*  
CD34+/CD38−/CD25+ cells   100% 
CD34+/CD38−/CD25− cells     52% 
Patient #34*  
CD34+/CD38−/CD25+ cells   100% 
CD34+/CD38−/CD25− cells     49% 
Patient #50*  
CD34+/CD38−/CD25+ cells   100% 
CD34+/CD38−/CD25− cells     30% 
---------------------------------------------------------------------------- 
Fluorescence in situ hybridization (FISH) was performed on 
sorted stem cell fractions. FISH was performed as described in 
the methods-section in this appendix. A total number of at least 
20 interphases were examined in each cell sample. 
*Patient numbers (#) refer to the list of patients provided in 
Supplementary Table S2. 
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Supplementary Table S5A  
 
Major genes up-regulated by gene array analysis on KU812 cells transduced with a CD25 
shRNA (KU812 CD25 shRNA, clone #2) compared to KU812 cells transduced with a random 
control shRNA (KU812 RDM shRNA)  
--------------------------------------------------------------------------------------------------------------------------- 
     Gene Array Data 
    KU812 CD25 shRNA vs  
up-regulated gene products (mRNA)       KU812 RDM shRNA 
Gene Symbol Name, Synonym(s), Abbreviation(s)    fold up-regulation  
   Gene Description 
--------------------------------------------------------------------------------------------------------------------------- 
DAZ2   deleted in azoospermia 2        25.6 
DAZ4   deleted in azoospermia 4        23.2 
DAZ3   deleted in azoospermia 3        22.7 
DAZ1   deleted in azoospermia 1       19.5 
USP26  ubiquitin specific peptidase 26       15.6 
---   TCONS_00014766 
linc-ZFHX4-2 chr8:+:76851941-76864003      8.9 
RAB27B   RAB27B, member RAS oncogene family     8.7 
IGFBP7   insulin-like growth factor binding protein 7     8.4 
SSX2   synovial sarcoma, X breakpoint 2      8.1 
---   ENST00000524132 
cdna:known chromosome:GRCh37:8:36394909:36636682:-1  
gene:ENSG00000253363       7.2 
---   TCONS_l2_00021973 
linc-SCLT1-4 chr4:-:132851185-132897107    6.8 
RASGEF1A  RasGEF domain family, member 1A      6.5 
---   TCONS_00008716 
linc-TRIML2-5 chr4:-:190200224-190201335   6.5 
---   TCONS_00014696 
linc-SNTG1-2 chr8:+:50080641-50105812    6.4 
SSX1   synovial sarcoma, X breakpoint 1      5.8 
IGF1    insulin-like growth factor 1 (somatomedin C)    5.8 
---   TCONS_00025434 
linc-KIF2B-1 chr17:+:50995287-51004254    5.7 
ZFP42   zinc finger protein 42 homolog (mouse)     5.5 
HBE1   hemoglobin, epsilon 1        5.1 
DSCR8   Down syndrome critical region gene 8     5.1 
MAGEA6   melanoma antigen family A, 6       4.7 
---   TCONS_00026582 
linc-MBP-7 chr18:-:75701644-75702115     4.6 
ARHGAP32  Rho GTPase activating protein 32      4.6 
---   TCONS_l2_00025436 
linc-MAP3K7-4 chr6:-:93432720-93433547    4.4 
FSTL5   follistatin-like 5         4.4 
INHBA   inhibin, beta A         4.3 
DSCR4   Down syndrome critical region gene 4     4.3 
---   TCONS_00026222 
linc-MBP-1 chr18:-:75683254-75692482     4.2 
---   TCONS_00015680 
linc-ANKRD20A1-14 chr9:+:45484571-45488153   4.1 
--------------------------------------------------------------------------------------------------------------------------- 
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     Gene Array Data 
    KU812 CD25 shRNA vs  
up-regulated gene products (mRNA)       KU812 RDM shRNA 
Gene Symbol Name, Synonym(s), Abbreviation(s)    fold up-regulation  
   Gene Description 
--------------------------------------------------------------------------------------------------------------------------- 
SNORD62A  small nucleolar RNA, C/D box 62A      4.1 
GRID2   glutamate receptor, ionotropic, delta 2     4.1 
HEPH   hephaestin          4.0 
CXADRP3   coxsackie virus and adenovirus receptor pseudogene 3   4.0 
SNORD85   small nucleolar RNA, C/D box 85      4.0 
RRAGD   Ras-related GTP binding D       4.0 
MIR4266   microRNA 4266         3.9 
ZNF385D-AS1  ZNF385D antisense RNA 1 (non-protein coding)    3.8 
CTSE   cathepsin E          3.7 
ENPP6   ectonucleotide pyrophosphatase/phosphodiesterase 6   3.7 
MAGEA12   melanoma antigen family A, 12      3.7 
ENPP5   ectonucleotide pyrophosphatase/phosphodiesterase 5   3.6 
---   TCONS_00017351 
linc-CHM-1 chrX:-:86979060-86983512    3.5 
---   TCONS_l2_00027522 
linc-XRCC2-3 chr7:-:153097004-153109319   3.5 
SAMD5   sterile alpha motif domain containing 5     3.5 
CSAG2   CSAG family, member 2       3.4 
NPC1L1   NPC1 (Niemann-Pick disease, type C1, gene)-like 1   3.4 
CRYBA4  crystallin, beta A4         3.3 
--------------------------------------------------------------------------------------------------------------------------- 
After calculating the differences in mRNA expression levels from paired samples, top up-regulated genes were 
selected and expressed as fold up-regulation in KU812 CD25 shRNA cells compared to KU812 RDM shRNA 
cells. Genes are listed in the order of up-regulation.  
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Supplementary Table S5B  
 
Major genes down-regulated by gene array analysis on KU812 cells transduced with a CD25 
shRNA (KU812 CD25 shRNA, clone #2) compared to KU812 cells transduced with a random 
control shRNA (KU812 RDM shRNA)  
--------------------------------------------------------------------------------------------------------------------------- 
     Gene Array Data 
    KU812 CD25 shRNA vs  
down-regulated gene products (mRNA)      KU812 RDM shRNA 
Gene Symbol Name, Synonym(s), Abbreviation(s)    fold down-regulation  
   Gene Description 
--------------------------------------------------------------------------------------------------------------------------- 
MS4A2   membrane-spanning 4-domains      0.1 
CYTL1   cytokine-like 1         0.2 
SIGLEC17P  sialic acid binding Ig-like lectin 17     0.2 
CPA3   carboxypeptidase A3 (mast cell)      0.2 
IL-2RA   interleukin 2 receptor, alpha       0.2 
---   TCONS_l2_00021793  
linc-ZFP42-7 chr4:+:188334717-188336851    0.2 
CDK15   cyclin-dependent kinase 15       0.2 
SIGLEC6   sialic acid binding Ig-like lectin      0.3 
CRISP3   cysteine-rich secretory protein 3      0.3 
PAH    phenylalanine hydroxylase       0.3 
HEY1   hairy/enhancer-of-split related, YRPW motif 1    0.3 
SLAMF6   SLAM family member 6        0.3 
GPR65   G protein-coupled receptor 65       0.3 
---   ENST00000522354 
havana:lincRNA chromosome:GRCh37:8:69760977:69764998:-1  
gene:ENSG00000254337       0.3 
CXCL10  chemokine (C-X-C motif) ligand 10      0.3 
RN5S126   RNA, 5S ribosomal 126        0.3 
---   TCONS_00017655 
linc-RBMY1B chrY:+:23300673-23332061    0.3 
---   TCONS_00011730  
linc-HDGFL1-1 chr6:+:22349446-22517940   0.3 
IL-1RL1  interleukin 1 receptor-like 1       0.3 
IGLV2-18   immunoglobulin lambda variable 2-18     0.3 
SLC18A2   solute carrier family 18, member 2      0.4 
SNAI2   snail homolog 2 (Drosophila)       0.4 
CA2    carbonic anhydrase II        0.4 
SGK1   serum/glucocorticoid regulated kinase 1     0.4 
---   ENST00000408076 
ncrna:miRNA chromosome:GRCh37:8:29786121:29786205:1  
gene:ENSG00000221003 gene_biotype:miRNA    0.4 
TMPRSS11F  transmembrane protease, serine 11F      0.4 
MIR181B1   microRNA 181b-1        0.4 
LUST   RBM5 antisense RNA        0.4 
PPAP2A   phosphatidic acid phosphatase type 2A     0.4 
---   TCONS_00001394 
linc-LRRC38-3 chr1:-:14717544-14746458    0.4 
RAB37  RAB37, member RAS oncogene family     0.4 
 
 
--------------------------------------------------------------------------------------------------------------------------- 
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     Gene Array Data 
    KU812 CD25 shRNA vs  
down-regulated gene products (mRNA)      KU812 RDM shRNA 
Gene Symbol Name, Synonym(s), Abbreviation(s)    fold down-regulation  
   Gene Description 
--------------------------------------------------------------------------------------------------------------------------- 
---   ENST00000364556   
ncrna:misc_RNA chromosome:GRCh37:3:110445868:110445968:1 
gene:ENSG00000201426       0.4 
RNU7-27P   RNA, U7 small nuclear 27 pseudogene     0.4 
---   ENST00000362601    
ncrna:misc_RNA chromosome:GRCh37:1:202884008:202884108:-1  
gene:ENSG00000199471       0.4 
---   BC016361  
Homo sapiens, clone IMAGE:4105785, mRNA   0.4 
---   ENST00000458954 
ncrna:miRNA chromosome:GRCh37:8:12435514:12435661:1  
gene:ENSG00000238460  
gene_biotype:miRNA transcript_biotype:miRNA    0.4 
TRAF5   Homo sapiens TNF receptor-associated factor 5    0.4 
---   ENST00000408265  
ncrna:miRNA chromosome:GRCh37:7:96920826:96920908:-1  
gene:ENSG00000221192       0.4 
BCL2   B-cell CLL/lymphoma 2        0.4 
---   ENST00000459100  
ncrna:miRNA chromosome:GRCh37:8:12493613:12493761:1  
gene:ENSG00000238323 gene_biotype:miRNA    0.4 
41XAF1   XIAP associated factor 1       0.4 
PRR9   proline rich 9         0.4 
IKZF2   IKAROS family zinc finger 2 (Helios)     0.4 
MIR548I3   microRNA 548i-3         0.4 
---   TCONS_00014864 
linc-KHDRBS3-5 chr8:+:135732687-135736134   0.4 
RN5S82   RNA, 5S ribosomal 82        0.4 
LIMD2   LIM domain containing 2       0.4 
GPR174   G protein-coupled receptor 174      0.4 
MAOB   monoamine oxidase B        0.4 
---   TCONS_00005769 
linc-ANO10-2 chr3:-:44462618-44465499    0.4 
--------------------------------------------------------------------------------------------------------------------------- 
After calculating the differences in mRNA expression levels from paired samples, top down-regulated genes 
were selected and expressed as fold down-regulation in KU812 CD25 shRNA cells compared to KU812 RDM 
shRNA cells. Genes are listed in the order of down-regulation.  
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Supplementary Figure S1   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
          
 
CML LSCs co-express CD25 together with other stem cell markers 
A: Histograms show the expression of CD26, CD33, CD44, CD52, CD117 and IL-1RAP on 
CD34+/CD38─ LSCs from one patient with CML chronic phase (CP, n=1, upper panels) and 
one patient with CML blast phase (BP, n=1, lower panels). The reactivity of CD34+/CD38─ 
LSCs with 2 different CD25 mAb (2A3 and BC96) was also tested in the patient with CML 
CP (upper histograms). Black open histograms represent the matched isotype control, red 
histograms represent expression of investigated surface antigens. The patient-numbers (#) are 
also indicated and refer to the list of patients shown in Supplementary Table S2. B: 
Correlations between the percentages of CD25+ stem cells, SCs (of CD34+/CD38─ SC) and 
CD26+ SCs (n=46, upper panel) and between CD25+ SCs and IL-1RAP+ SCs (n=36, lower 
panel) in the bone marrow or blood of patients with BCR/ABL1+ CML. 
B A 
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Supplementary Figure S2 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of BCR/ABL1 in CD34+/CD38−/CD25+ stem cells obtained from a patient 
with CML as determined by fluorescence in situ hybridization (FISH) 
FISH analysis was performed using purified CD34+/CD38−/CD25+ CML stem cells (left 
panel) and CD34+/CD38−/CD25− stem cells (right panel) obtained from one (the same) patient 
with CML (#34, see Supplementary Table S2). FISH was performed on cytospin slides using 
a triple-color staining approach, with one probe specific for ABL1 (red) and two specific for 
BCR (green and blue). Red-green and red-blue fusion-spots indicate BCR/ABL1. Quantitative 
FISH data are shown in Supplementary Table S4. 
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Supplementary Figure S3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clonogenic growth of CML LSCs and normal stem cells obtained from two patients 
with Ph+ CML  
CD34+/CD38−/CD25− (presumably normal) stem cells and CD34+/CD38−/CD25+ LSCs were 
highly enriched (purity >95%) from bone marrow mononuclear cells in two patients with 
chronic phase CML (patient #38 and #52 in Supplementary Table S2) by flow cytometry. 
CD25− (presumably normal) stem cells and LSCs were cultured on irradiated M2-10B4 
feeder-cells in LTC-IC (Myelocult) medium for 3 weeks. Then, cells were harvested and 
cultured in a CFU-GM culture assay (Methocult containing colony-stimulating cytokines) for 
2 weeks. CFU-GM (blue bars) and BFU-E colonies (red bars) were counted under an inverted 
microscope. Results show the numbers of colonies per 1,000 plated cells and represent the 
mean±S.D. of triplicates. After counting, colonies were picked and pooled (10 colonies per 
plate) and the isolated RNA subjected to qPCR analysis to measure BCR/ABL1 levels. In 
colonies grown from CD34+/CD38−/CD25+ LSCs, almost all cells were found to be 
BCR/ABL1+ (>80%), whereas in the CD34+/CD38−/CD25− (presumably normal) stem cells, 
BCR/ABL1 mRNA levels were low or undetectable (0-5.2%). 
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Supplementary Figure S4 
 
 
 
 
 
 
 
 
 
 
 
 
Western blotting confirmed the knock-down of STAT5 in KU812 cells 
Western blotting was performed with untransduced KU812 cells (control) and KU812 cells 
transduced with a random control shRNA (RDM shRNA) or a shRNA against STAT5 
(STAT5 shRNA) as described in the Material and Methods part in the main document, using 
an antibody against STAT5. Akt served as a loading control. 
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Supplementary Figure S5A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug-induced upregulation of CD25 in CML cell lines 
KCL-22 cells (upper panels), K562 cells (middle panels), and K562-R cells (lower panels) 
were incubated in control medium (Co) or various concentrations of BEZ235 (left panels), 
RAD001 (middle panels), or LY294002 (right panels) (each 0.03-3 µM) at 37°C for 24 hours. 
Thereafter, expression of CD25 on these cell lines (percent of CD25-positive cells) was 
assessed by flow cytometry. Results are expressed as percent of control (percent CD25+ cells 
in Co = 100%) and represent the mean±S.D. from at least 5 independent experiments. 
Asterisk (*): p<0.05 compared to untreated cells (Co). 
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Supplementary Figure S5B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effects of BEZ235 on CD25 surface expression in Ba/F3 cells expressing diverse 
BCR/ABL1 mutant forms 
Ba/F3 cells expressing several BCR/ABL1 mutants (as indicated) were incubated in control 
medium (control) or in various concentrations of BEZ235 (1 and 5 µM) or DMSO control at 
37°C for 24 hours. After incubation, cells were analyzed for their CD25 surface expression 
using flow cytometry. Results are expressed as mean fluorescence intensities (MFI) of CD25 
(percent of medium control) and represent the mean±SD from 3 independent experiments. 
Asterisk (*) indicates p<0.05 compared to untreated cells. 
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Supplementary Figure S5C  
 
Effects of the dual PI3K/mTOR blocker 
BEZ235 on proliferation of Ba/F3 cells 
expressing diverse BCR/ABL1 mutants 
-------------------------------------------------------------- 
BCR/ABL1 mutant     IC50 
       [µM] 
-------------------------------------------------------------- 
wild type (WT)     0.5-1 
M244V      0.1-0.5 
G250E      0.1-0.5 
Q252H      0.1-0.5 
Y253H      0.5-1 
E255K      0.1-0.5 
E255V      0.1-0.5 
T315I      0.1-0.5 
F317L      0.1-0.5 
F317V      0.1-0.5 
F359V      0.5-1 
H396P      0.5-1 
-------------------------------------------------------------- 
Ba/F3 cells were incubated with various 
concentrations of BEZ235 at 37°C for 48 hours. 
Proliferation was measured by analyzing 3H-
thymidine uptake.  
IC50, inhibitory concentration (50%). 
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Supplementary Figure S6A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effects of imatinib on CD25 surface expression in Ba/F3 cells expressing diverse 
BCR/ABL1 mutants 
Ba/F3 cells expressing several BCR/ABL1 mutants were incubated in control medium 
(control) or in various concentrations of imatinib (1 µM) at 37°C for 24 hours. After 
incubation, cells were analyzed for their CD25 surface expression using flow cytometry. 
Results are expressed as MFI of CD25 (percent of control) and represent the mean±SD from 3 
independent experiments. Asterisk (*) indicates p<0.05 compared to untreated cells. 
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Supplementary Figure S6B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effects of nilotinib on CD25 surface expression in Ba/F3 cells expressing various 
imatinib-resistant BCR/ABL1 mutants 
Ba/F3 cells expressing BCR/ABL1 mutants were incubated in control medium (control) or in 
medium containing nilotinib (10 nM or 100 nM) at 37°C for 24 hours. After incubation, cells 
were analyzed for CD25 expression by flow cytometry. Results are expressed as MFI of 
CD25 (percent of medium control) and represent the mean±SD from 3 independent 
experiments. Asterisk (*) indicates p<0.05 compared to untreated cells (control). 
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Supplementary Figure S6C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effects of ponatinib on CD25 expression in Ba/F3 cells expressing various BCR/ABL1 
mutants 
Ba/F3 cells expressing various imatinib-resistant BCR/ABL1 mutants were incubated in 
control medium (control) or in medium containing ponatinib (10 nM or 100 nM) at 37°C for 
24 hours. After incubation, cells were analyzed for CD25 expression by flow cytometry. 
Results are expressed as MFI of CD25 (percent of medium control) and represent the 
mean±SD from 3 independent experiments. Asterisk (*) indicates p<0.05 compared to 
untreated cells (control). 
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Supplementary Figure S7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effects of interleukin-2 (IL-2) on growth of untreated and BEZ235-treated CML cells 
Upper panels: KU812, K562 or mononuclear cells (MNCs) from two patients with chronic 
phase (CP) CML were incubated in control medium or in various concentrations of IL-2 (100-
2,000 ng/ml) at 37°C for 48 hours. After incubation, 3H-thymidine uptake was measured. 
Middle and lower panels: KU812 and K562 cells (middle panels) or MNCs from a patient 
with CP CML, from a TKI-resistant CML patient and from a CML patient with complete 
cytogenetic response (CCyR) (lower panels) were pre-incubated in control medium (black 
line) or medium supplemented with 1 µg/ml rhIL-2 (red line) at 37°C for 1 hour. After 
incubation, cells were washed and incubated in control medium or in various concentrations 
of BEZ235 at 37°C for 48 hours. Thereafter, 3H-thymidine uptake was measured. Results are 
expressed as percent of control and represent the mean±SD from at least 3 independent 
experiments (KU812 and K562 cells) or represent the mean±SD from triplicates (CML 
MNCs). The patient-numbers (#) refer to Supplementary Table S2. 
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Supplementary Figure S8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of transduced CD25 on growth of CML cells lines 
KCL-22 cells (left panel), K562 cells (middle panel), or K562-R cells (right panel) were 
transduced with a LentiORF IL2RA (CD25) gene construct, and purified by cell sorting 
(GFP+ cells). Then, CD25-transduced cells were mixed 1:1 with KU812 cells transduced with 
a control construct (empty vector) and cultured at 37°C. The percentage of CD25+ cells in 
these cultures was analyzed 3 times a week by flow cytometry using an APC-conjugated mAb 
(BC96) directed against CD25. Results show the percent of CD25+ cells and represent the 
mean±S.D. from 6 independent experiments. Asterisk (*): p<0.05 compared to percent CD25+ 
cells measured on day 0. 
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Supplementary Figure S9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathway analysis of KU812 cells transduced with a CD25 shRNA 
KU812 cells were transduced with a shRNA against CD25 (clone #2) or a RDM control 
shRNA as described in the text of the main document. Transduced cells were subjected to 
RNA isolation and gene array analysis using Affymetrix technology to determine CD25 
shRNA-induced upregulation and downregulation of genes. All genes that were at least two-
fold (up- or down-) regulated by CD25 shRNA-transduction were applied to pathway 
enrichment analyses using the panther program (www.pantherdb.org). As visible, these 
analyses revealed a significant enrichment of upregulated genes (blue bars) and 
downregulated genes (red bars) in certain pathways related to growth, signal transduction, or 
cell death. The figure shows the pathway enrichment factor of significantly influenced 
pathways (p<0.05) determined by the PANTHER program and statistical evaluation after 
Bonferroni correction as described (15). 
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Supplementary Figure S10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effects of shRNA-induced knock-down of CD25 on cell cycle progression and apoptosis 
in KU812 cells 
Untransduced KU812 cells (open bars) and KU812 cells transduced with a random (RDM) 
shRNA (black bars) or CD25 shRNA (clone #2, gray bars) were spun on cytospin-slides and 
stained with Wright-Giemsa. Mitotic cells (upper left panel) and apoptotic cells (upper right 
panel) were counted on Wright-Giemsa-stained slides under an inverted microscope 
(Olympus, Tokyo, Japan). Results are expressed as percent of mitotic/apoptotic cells (of all 
cells) and represent the mean±SD from 3 independent experiments. Flow cytometric cell 
cycle anaylsis did not reveal a significant difference in the percentage of cells in G1 or S 
phase in untransduced KU812 cells and KU812 cells transduced with RDM shRNA or CD25 
shRNA. Results are expressed as percent PI-positive cells and represent the mean±SD from 6 
independent experiments (lower left panel). Apoptosis was also determined by flow 
cytometry, using an antibody against active caspase-3 (lower right panel). Results are 
expressed as percent caspase-3 positive cells and represent the mean±SD from 5 independent 
experiments. 
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Supplementary Figure S11A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effects of shRNA-induced knock-down of CD25 on the responsiveness of KU812 cells to 
imatinib, nilotinib, ponatinib and BEZ235 
Untransduced KU812 cells (○-○) and KU812 cells transduced with a random control (RDM) 
shRNA (▲-▲) or a CD25 shRNA (clone #2, ■-■) were incubated in control medium 
(control) or in various concentrations of imatinib, nilotinib, ponatinib or BEZ235 at 37°C for 
48 hours. In the lower right panel, the DMSO solvent control is also shown. After incubation, 
3H-thymidine uptake was measured. Results are expressed as percent of control (untransduced 
KU812 cells) and represent the mean±SD from 3 independent experiments. 
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Supplementary Figure S11B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The PI3K/mTOR blocker BEZ235 synergize with imatinib, nilotinib and ponatinib in 
inducing growth inhibition in KU812 cells 
KU812 cells were incubated in control medium (control) or in various concentrations of 
BEZ235 alone or in combination with the BCR/ABL1 tyrosine kinase inhibitors imatinib 
(upper panel), nilotinib (middle panel) or ponatinib (lower panel) at fixed ratio of drug 
concentrations at 37°C for 48 hours. After incubation, 3H-thymidine uptake was measured. 
Results are expressed as percent of control (0) and represent the mean±SD from triplicates. In 
each case, the combination index value (CI) was calculated by Calcusyn software (right 
panels). A CI of 1 indicates an additive effect, a CI below 1 a synergistic drug-interaction, and 
a CI greater than 1 an antagonistic effect.  
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